|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
decreases activity decreases expression multiple interactions |
EXP ISO |
bosentan metabolite results in decreased activity of ABCB11 protein; bosentan results in decreased activity of ABCB11 protein Bosentan results in decreased expression of ABCB11 mRNA bosentan results in decreased expression of ABCB11 mRNA bosentan inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] |
CTD |
PMID:11309550 PMID:15465654 PMID:15509663 PMID:20829430 PMID:23956101 PMID:24014644 PMID:27765674 PMID:29761207 More...
|
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
decreases expression |
ISO |
bosentan results in decreased expression of ABCB1 mRNA |
CTD |
PMID:28369585 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
decreases expression |
ISO |
Bosentan results in decreased expression of ABCB4 mRNA |
CTD |
PMID:29761207 |
|
NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
increases expression decreases expression |
EXP ISO |
bosentan results in increased expression of ABCC2 mRNA Bosentan results in increased expression of ABCC2 mRNA bosentan results in decreased expression of ABCC2 mRNA |
CTD |
PMID:27765674 PMID:28369585 PMID:29761207 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
increases expression decreases expression |
EXP ISO |
bosentan results in increased expression of ABCC3 mRNA bosentan results in decreased expression of ABCC3 mRNA |
CTD |
PMID:27765674 PMID:28369585 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
increases expression |
EXP |
bosentan results in increased expression of ABCC4 mRNA |
CTD |
PMID:27765674 |
|
NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283
|
|
G |
Abcg5 |
ATP binding cassette subfamily G member 5 |
increases expression affects expression |
EXP ISO |
bosentan results in increased expression of ABCG5 mRNA Bosentan affects the expression of ABCG5 mRNA |
CTD |
PMID:27765674 PMID:29761207 |
|
NCBI chr 6:9,965,118...9,990,563
Ensembl chr 6:9,965,118...9,990,563
|
|
G |
Abcg8 |
ATP binding cassette subfamily G member 8 |
increases expression |
EXP |
bosentan results in increased expression of ABCG8 mRNA |
CTD |
PMID:27765674 |
|
NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912
|
|
G |
Adh1 |
alcohol dehydrogenase 1C (class I), gamma polypeptide |
decreases expression |
ISO |
Bosentan results in decreased expression of ADH1C mRNA; Bosentan results in decreased expression of ADH1C protein |
CTD |
PMID:29761207 |
|
NCBI chr 2:226,797,303...226,808,892
Ensembl chr 2:226,797,303...226,808,892
|
|
G |
Adh4 |
alcohol dehydrogenase 4 (class II), pi polypeptide |
decreases expression |
ISO |
Bosentan results in decreased expression of ADH4 mRNA; Bosentan results in decreased expression of ADH4 protein |
CTD |
PMID:29761207 |
|
NCBI chr 2:226,948,717...226,966,747
Ensembl chr 2:226,947,466...226,987,591
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
multiple interactions |
ISO |
bosentan inhibits the reaction [EDN1 protein results in increased expression of ADRB2 mRNA] |
CTD |
PMID:22483689 |
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Aldh8a1 |
aldehyde dehydrogenase 8 family, member A1 |
affects expression |
ISO |
Bosentan affects the expression of ALDH8A1 mRNA |
CTD |
PMID:29761207 |
|
NCBI chr 1:16,183,940...16,203,385
Ensembl chr 1:16,183,940...16,203,385
|
|
G |
Aldob |
aldolase, fructose-bisphosphate B |
decreases expression |
ISO |
Bosentan results in decreased expression of ALDOB mRNA; Bosentan results in decreased expression of ALDOB protein |
CTD |
PMID:29761207 |
|
NCBI chr 5:63,889,045...63,902,086
Ensembl chr 5:63,889,046...63,902,116
|
|
G |
Ascl1 |
achaete-scute family bHLH transcription factor 1 |
affects expression |
ISO |
Bosentan affects the expression of ASCL1 mRNA |
CTD |
PMID:29761207 |
|
NCBI chr 7:21,904,153...21,906,003
Ensembl chr 7:21,903,126...21,905,993
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
bosentan inhibits the reaction [Doxorubicin results in increased expression of BAX protein] |
CTD |
PMID:17974986 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
C9 |
complement C9 |
affects expression |
ISO |
Bosentan affects the expression of C9 mRNA |
CTD |
PMID:29761207 |
|
NCBI chr 2:55,573,094...55,621,345
Ensembl chr 2:55,572,992...55,621,338
|
|
G |
Car12 |
carbonic anhydrase 12 |
affects expression |
ISO |
Bosentan affects the expression of CA12 mRNA |
CTD |
PMID:29761207 |
|
NCBI chr 8:67,274,739...67,330,428
Ensembl chr 8:67,274,359...67,330,440
|
|
G |
Cat |
catalase |
decreases expression |
ISO |
Bosentan results in decreased expression of CAT mRNA |
CTD |
PMID:29761207 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Col1a2 |
collagen type I alpha 2 chain |
decreases expression |
ISO |
bosentan results in decreased expression of COL1A2 protein |
CTD |
PMID:11729239 |
|
NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867
|
|
G |
Cps1 |
carbamoyl-phosphate synthase 1 |
decreases expression |
ISO |
Bosentan results in decreased expression of CPS1 mRNA; Bosentan results in decreased expression of CPS1 protein |
CTD |
PMID:29761207 |
|
NCBI chr 9:68,614,153...68,737,037
Ensembl chr 9:68,614,153...68,737,033
|
|
G |
Cxadr |
CXADR, Ig-like cell adhesion molecule |
decreases expression multiple interactions |
ISO |
bosentan results in decreased expression of CXADR mRNA; bosentan results in decreased expression of CXADR protein EDN1 protein inhibits the reaction [bosentan results in decreased expression of CXADR mRNA] |
CTD |
PMID:20392896 |
|
NCBI chr11:16,982,752...17,030,078
Ensembl chr11:16,982,860...17,030,046
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
increases expression |
ISO |
Bosentan results in increased expression of CYP2B6 mRNA |
CTD |
PMID:18332078 PMID:29761207 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp3a18 |
cytochrome P450, family 3, subfamily a, polypeptide 18 |
affects expression |
ISO |
Bosentan affects the expression of CYP3A43 mRNA |
CTD |
PMID:29761207 |
|
NCBI chr12:8,880,528...8,930,382
Ensembl chr12:8,880,528...8,930,381
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
increases expression |
ISO |
Bosentan results in increased expression of CYP3A4 mRNA |
CTD |
PMID:18332078 PMID:29761207 |
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
decreases expression |
ISO |
Bosentan results in decreased expression of CYP7A1 mRNA |
CTD |
PMID:29761207 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Dclk1 |
doublecortin-like kinase 1 |
affects expression |
ISO |
Bosentan affects the expression of DCLK1 mRNA |
CTD |
PMID:29761207 |
|
NCBI chr 2:139,417,234...139,710,956
Ensembl chr 2:139,417,163...139,710,956
|
|
G |
Dlx6 |
distal-less homeobox 6 |
decreases expression |
ISO |
bosentan results in decreased expression of DLX6 mRNA |
CTD |
PMID:15063187 |
|
NCBI chr 4:34,984,264...34,989,926
Ensembl chr 4:34,984,232...34,991,343
|
|
G |
Edn1 |
endothelin 1 |
decreases activity decreases expression multiple interactions |
EXP ISO |
bosentan results in decreased activity of EDN1 protein bosentan results in decreased expression of EDN1 protein bosentan inhibits the reaction [EDN1 protein results in increased expression of ADRB2 mRNA]; bosentan inhibits the reaction [Oxotremorine results in increased activity of EDN1 protein]; bosentan inhibits the reaction [TGFB1 protein results in increased activity of EDN1 protein]; EDN1 protein inhibits the reaction [bosentan results in decreased expression of CXADR mRNA] 3,5-dibromosalicylic acid inhibits the reaction [bosentan inhibits the reaction [EDN1 protein binds to EDNRA protein]]; bosentan binds to and results in decreased activity of EDN1 protein; bosentan inhibits the reaction [EDN1 protein binds to EDNRA protein]; bosentan inhibits the reaction [Monocrotaline results in increased expression of EDN1 mRNA] |
CTD |
PMID:10474778 PMID:10961375 PMID:11093786 PMID:16431896 PMID:20392896 PMID:20967148 PMID:22483689 PMID:22796455 More...
|
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Edn3 |
endothelin 3 |
decreases activity |
EXP |
bosentan results in decreased activity of EDN3 protein |
CTD |
PMID:10961375 |
|
NCBI chr 3:163,562,307...163,586,636
Ensembl chr 3:163,562,520...163,585,093
|
|
G |
Ednra |
endothelin receptor type A |
multiple interactions |
ISO EXP |
bosentan binds to and results in decreased activity of EDNRA protein 3,5-dibromosalicylic acid inhibits the reaction [bosentan inhibits the reaction [EDN1 protein binds to EDNRA protein]]; bosentan binds to and results in decreased activity of EDNRA protein; bosentan inhibits the reaction [EDN1 protein binds to EDNRA protein] |
CTD |
PMID:11093786 PMID:15964565 PMID:16219361 |
|
NCBI chr19:30,233,540...30,303,727
Ensembl chr19:30,233,571...30,297,049
|
|
G |
Ednrb |
endothelin receptor type B |
multiple interactions |
ISO |
bosentan binds to and results in decreased activity of EDNRB protein |
CTD |
PMID:16219361 |
|
NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
decreases expression |
ISO |
Bosentan results in decreased expression of FABP1 mRNA; Bosentan results in decreased expression of FABP1 protein |
CTD |
PMID:29761207 |
|
NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788
|
|
G |
Fn1 |
fibronectin 1 |
multiple interactions |
ISO |
bosentan inhibits the reaction [Glucose results in increased expression of FN1 mRNA]; bosentan inhibits the reaction [Glucose results in increased expression of FN1 protein] |
CTD |
PMID:12388107 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
G0s2 |
G0/G1switch 2 |
affects expression |
ISO |
Bosentan affects the expression of G0S2 mRNA |
CTD |
PMID:29761207 |
|
NCBI chr13:104,806,351...104,807,263
Ensembl chr13:104,806,156...104,807,451
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
affects expression |
ISO |
Bosentan affects the expression of G6PC1 mRNA |
CTD |
PMID:29761207 |
|
NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
|
|
G |
Gata4 |
GATA binding protein 4 |
multiple interactions affects activity |
ISO EXP |
bosentan inhibits the reaction [Doxorubicin results in decreased expression of GATA4 mRNA]; bosentan inhibits the reaction [Doxorubicin results in decreased expression of GATA4 protein] bosentan affects the activity of GATA4 protein |
CTD |
PMID:17974986 PMID:21084678 |
|
NCBI chr15:37,459,601...37,531,291
Ensembl chr15:37,459,601...37,505,636
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression |
ISO |
Bosentan results in increased expression of GCLC mRNA |
CTD |
PMID:29761207 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP |
Bosentan inhibits the reaction [[sodium arsenite results in increased abundance of Arsenic] which results in increased activity of GPT protein] |
CTD |
PMID:33026618 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
decreases expression |
ISO |
Bosentan results in decreased expression of GPX1 mRNA |
CTD |
PMID:29761207 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gstt2 |
glutathione S-transferase, theta 2 |
decreases expression |
ISO |
Bosentan results in decreased expression of GSTT2 mRNA |
CTD |
PMID:29761207 |
|
NCBI chr20:12,819,617...12,823,288
Ensembl chr20:12,819,170...12,823,288
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
ISO |
Bosentan results in increased expression of HMOX1 mRNA |
CTD |
PMID:29761207 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hnf4a |
hepatocyte nuclear factor 4, alpha |
decreases expression |
ISO |
Bosentan results in decreased expression of HNF4A mRNA |
CTD |
PMID:29761207 |
|
NCBI chr 3:152,186,787...152,248,320
Ensembl chr 3:152,186,787...152,248,320
|
|
G |
Hsd3b1 |
hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 |
affects expression |
ISO |
Bosentan affects the expression of HSD3B1 mRNA |
CTD |
PMID:29761207 |
|
NCBI chr 2:186,169,864...186,175,984
Ensembl chr 2:186,169,863...186,175,999
|
|
G |
Igf1 |
insulin-like growth factor 1 |
affects expression |
ISO |
Bosentan affects the expression of IGF1 mRNA |
CTD |
PMID:29761207 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Il6 |
interleukin 6 |
increases expression |
ISO |
Bosentan results in increased expression of IL6 mRNA |
CTD |
PMID:29761207 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Inhbe |
inhibin subunit beta E |
affects expression |
ISO |
Bosentan affects the expression of INHBE mRNA |
CTD |
PMID:29761207 |
|
NCBI chr 7:63,177,558...63,178,983
Ensembl chr 7:63,176,219...63,179,172
|
|
G |
Kmo |
kynurenine 3-monooxygenase |
affects expression |
ISO |
Bosentan affects the expression of KMO mRNA |
CTD |
PMID:29761207 |
|
NCBI chr13:87,557,080...87,589,334
Ensembl chr13:87,557,286...87,588,881
|
|
G |
Leap2 |
liver enriched antimicrobial peptide 2 |
affects expression |
ISO |
Bosentan affects the expression of LEAP2 mRNA |
CTD |
PMID:29761207 |
|
NCBI chr10:37,577,855...37,581,245
Ensembl chr10:37,577,855...37,581,244
|
|
G |
MGC105649 |
hypothetical LOC302884 |
affects expression |
ISO |
Bosentan affects the expression of C15ORF48 mRNA |
CTD |
PMID:29761207 |
|
NCBI chr 3:109,719,952...109,723,507
Ensembl chr 3:109,719,897...109,724,006 Ensembl chr 3:109,719,897...109,724,006
|
|
G |
Mgst1 |
microsomal glutathione S-transferase 1 |
decreases expression |
ISO |
Bosentan results in decreased expression of MGST1 mRNA |
CTD |
PMID:29761207 |
|
NCBI chr 4:171,029,666...171,044,893
Ensembl chr 4:171,029,630...171,044,892
|
|
G |
Mrc1 |
mannose receptor, C type 1 |
affects expression |
ISO |
Bosentan affects the expression of MRC1 mRNA |
CTD |
PMID:29761207 |
|
NCBI chr17:77,249,187...77,330,857
Ensembl chr17:77,249,187...77,330,857
|
|
G |
Mttp |
microsomal triglyceride transfer protein |
decreases expression |
ISO |
Bosentan results in decreased expression of MTTP mRNA |
CTD |
PMID:29761207 |
|
NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239
|
|
G |
Myh7 |
myosin heavy chain 7 |
multiple interactions |
ISO |
Bosentan inhibits the reaction [MYH7 gene mutant form results in increased expression of NPPB protein] |
CTD |
PMID:29741611 |
|
NCBI chr15:28,446,550...28,469,888
Ensembl chr15:28,446,550...28,468,217
|
|
G |
Nfix |
nuclear factor I X |
decreases expression |
ISO |
Bosentan results in decreased expression of NFIX mRNA |
CTD |
PMID:29761207 |
|
NCBI chr19:23,355,388...23,450,360
Ensembl chr19:23,355,498...23,448,265
|
|
G |
Nox4 |
NADPH oxidase 4 |
decreases expression |
ISO |
Bosentan results in decreased expression of NOX4 mRNA |
CTD |
PMID:29761207 |
|
NCBI chr 1:140,900,886...141,078,844
Ensembl chr 1:140,901,097...141,077,406
|
|
G |
Nppb |
natriuretic peptide B |
multiple interactions |
ISO |
Bosentan inhibits the reaction [MYH7 gene mutant form results in increased expression of NPPB protein] |
CTD |
PMID:29741611 |
|
NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression |
ISO |
Bosentan results in increased expression of NQO1 mRNA |
CTD |
PMID:29761207 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr1h2 |
nuclear receptor subfamily 1, group H, member 2 |
decreases expression |
ISO |
Bosentan results in decreased expression of NR1H2 mRNA |
CTD |
PMID:29761207 |
|
NCBI chr 1:95,041,967...95,047,377
Ensembl chr 1:95,041,967...95,047,377
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
decreases expression |
ISO |
Bosentan results in decreased expression of NR1H3 mRNA |
CTD |
PMID:29761207 |
|
NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
decreases expression |
ISO |
Bosentan results in decreased expression of NR1H4 mRNA |
CTD |
PMID:29761207 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Pck2 |
phosphoenolpyruvate carboxykinase 2 (mitochondrial) |
decreases expression |
ISO |
Bosentan results in decreased expression of PCK2 mRNA |
CTD |
PMID:29761207 |
|
NCBI chr15:29,027,891...29,036,729
Ensembl chr15:29,027,894...29,037,283
|
|
G |
Pglyrp2 |
peptidoglycan recognition protein 2 |
affects expression |
ISO |
Bosentan affects the expression of PGLYRP2 mRNA |
CTD |
PMID:29761207 |
|
NCBI chr 7:11,418,674...11,432,162
Ensembl chr 7:11,418,880...11,427,773
|
|
G |
Pklr |
pyruvate kinase L/R |
affects expression |
ISO |
Bosentan affects the expression of PKLR mRNA |
CTD |
PMID:29761207 |
|
NCBI chr 2:174,543,008...174,551,863
Ensembl chr 2:174,543,039...174,551,870
|
|
G |
Pon1 |
paraoxonase 1 |
decreases expression |
ISO |
Bosentan results in decreased expression of PON1 mRNA |
CTD |
PMID:29761207 |
|
NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360
|
|
G |
Por |
cytochrome p450 oxidoreductase |
affects expression |
ISO |
Bosentan affects the expression of POR mRNA |
CTD |
PMID:29761207 |
|
NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
decreases expression |
ISO |
Bosentan results in decreased expression of PPARG mRNA |
CTD |
PMID:29761207 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
decreases expression |
ISO |
Bosentan results in decreased expression of PPARGC1A mRNA |
CTD |
PMID:29761207 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
bosentan inhibits the reaction [Glucose results in increased activity of RELA protein] |
CTD |
PMID:12388107 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Sftpa1 |
surfactant protein A1 |
multiple interactions |
EXP |
Bosentan inhibits the reaction [Nitric Oxide Donors results in decreased expression of SFTPA1 mRNA]; Bosentan inhibits the reaction [Nitric Oxide results in decreased expression of SFTPA1 mRNA]; Bosentan inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased expression of SFTPA1 mRNA] |
CTD |
PMID:15640287 |
|
NCBI chr16:17,008,180...17,011,686
Ensembl chr16:17,008,180...17,011,685
|
|
G |
Sftpb |
surfactant protein B |
multiple interactions |
EXP |
bosentan inhibits the reaction [Nitric Oxide Donors results in decreased expression of SFTPB mRNA]; bosentan inhibits the reaction [Nitric Oxide results in decreased expression of SFTPB mRNA]; bosentan inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased expression of SFTPB mRNA] |
CTD |
PMID:15640287 |
|
NCBI chr 4:104,359,303...104,368,439
Ensembl chr 4:104,359,396...104,368,436
|
|
G |
Sftpc |
surfactant protein C |
multiple interactions |
EXP |
bosentan inhibits the reaction [Nitric Oxide Donors results in decreased expression of SFTPC mRNA]; bosentan inhibits the reaction [Nitric Oxide results in decreased expression of SFTPC mRNA]; bosentan inhibits the reaction [S-Nitroso-N-Acetylpenicillamine results in decreased expression of SFTPC mRNA] |
CTD |
PMID:15640287 |
|
NCBI chr15:45,596,565...45,599,615
Ensembl chr15:45,596,574...45,610,777
|
|
G |
Slc10a1 |
solute carrier family 10 member 1 |
decreases expression |
EXP ISO |
bosentan results in decreased expression of SLC10A1 mRNA Bosentan results in decreased expression of SLC10A1 mRNA |
CTD |
PMID:27765674 PMID:28369585 PMID:29761207 |
|
NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670
|
|
G |
Slc22a7 |
solute carrier family 22 member 7 |
affects expression |
ISO |
Bosentan affects the expression of SLC22A7 mRNA |
CTD |
PMID:29761207 |
|
NCBI chr 9:14,547,073...14,554,354
Ensembl chr 9:14,547,849...14,553,921
|
|
G |
Slc3a2 |
solute carrier family 3 member 2 |
increases expression |
ISO |
Bosentan results in increased expression of SLC3A2 mRNA; Bosentan results in increased expression of SLC3A2 protein |
CTD |
PMID:29761207 |
|
NCBI chr 1:205,604,468...205,618,931
Ensembl chr 1:205,604,468...205,618,931
|
|
G |
Slc51a |
solute carrier family 51 subunit alpha |
increases expression |
ISO |
Bosentan results in increased expression of SLC51A mRNA |
CTD |
PMID:29761207 |
|
NCBI chr11:68,299,086...68,313,485
Ensembl chr11:68,299,086...68,313,485
|
|
G |
Slc51b |
solute carrier family 51 subunit beta |
increases expression |
ISO |
Bosentan results in increased expression of SLC51B mRNA |
CTD |
PMID:29761207 |
|
NCBI chr 8:65,931,891...65,934,893
Ensembl chr 8:65,931,890...65,940,145
|
|
G |
Slc6a1 |
solute carrier family 6 member 1 |
affects expression |
ISO |
Bosentan affects the expression of SLC6A1 mRNA |
CTD |
PMID:29761207 |
|
NCBI chr 4:147,448,961...147,482,295
Ensembl chr 4:147,466,965...147,482,293
|
|
G |
Slco1a1 |
solute carrier organic anion transporter family, member 1a1 |
multiple interactions increases uptake |
EXP |
[biochanin A results in decreased activity of SLCO1B1 protein] which results in decreased uptake of Bosentan; [hispidulin results in decreased activity of SLCO1B1 protein] which results in decreased uptake of Bosentan; [isoliquiritigenin results in decreased activity of SLCO1B1 protein] which results in decreased uptake of Bosentan; [kaempferol results in decreased activity of SLCO1B1 protein] which results in decreased uptake of Bosentan; [licochalcone A results in decreased activity of SLCO1B1 protein] which results in decreased uptake of Bosentan; [Luteolin results in decreased activity of SLCO1B1 protein] which results in decreased uptake of Bosentan; [sinensetin results in decreased activity of SLCO1B1 protein] which results in decreased uptake of Bosentan SLCO1B1 protein results in increased uptake of Bosentan |
CTD |
PMID:32259555 |
|
NCBI chr 4:174,877,045...174,950,857
Ensembl chr 4:174,876,593...174,950,873
|
|
G |
Sod1 |
superoxide dismutase 1 |
decreases expression |
ISO |
Bosentan results in decreased expression of SOD1 mRNA |
CTD |
PMID:29761207 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
increases expression |
ISO |
Bosentan results in increased expression of SOD2 mRNA |
CTD |
PMID:29761207 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sult1e1 |
sulfotransferase family 1E member 1 |
affects expression |
ISO |
Bosentan affects the expression of SULT1E1 mRNA |
CTD |
PMID:29761207 |
|
NCBI chr14:20,422,324...20,439,562
Ensembl chr14:20,422,324...20,439,275
|
|
G |
Tat |
tyrosine aminotransferase |
affects expression |
ISO |
Bosentan affects the expression of TAT mRNA |
CTD |
PMID:29761207 |
|
NCBI chr19:37,947,153...37,957,717
Ensembl chr19:37,947,112...37,958,031
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
bosentan inhibits the reaction [TGFB1 protein results in increased activity of EDN1 protein] |
CTD |
PMID:22796455 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
bosentan inhibits the reaction [Doxorubicin results in increased expression of TNF protein] |
CTD |
PMID:17974986 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Txn2 |
thioredoxin 2 |
decreases expression |
ISO |
Bosentan results in decreased expression of TXN2 mRNA |
CTD |
PMID:29761207 |
|
NCBI chr 7:109,496,772...109,510,378
Ensembl chr 7:109,496,761...109,510,359
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
increases expression |
ISO |
Bosentan results in increased expression of TXNRD1 mRNA |
CTD |
PMID:29761207 |
|
NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863
|
|
G |
Ugt1a6 |
UDP glucuronosyltransferase family 1 member A6 |
decreases expression |
ISO |
Bosentan results in decreased expression of UGT1A6 mRNA |
CTD |
PMID:29761207 |
|
NCBI chr 9:88,747,229...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Vnn1 |
vanin 1 |
affects expression |
ISO |
Bosentan affects the expression of VNN1 mRNA |
CTD |
PMID:29761207 |
|
NCBI chr 1:21,537,084...21,547,395
Ensembl chr 1:21,537,094...21,547,395
|
|
G |
Xdh |
xanthine dehydrogenase |
decreases expression |
ISO |
Bosentan results in decreased expression of XDH mRNA |
CTD |
PMID:29761207 |
|
NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268
|
|
|
G |
Ednra |
endothelin receptor type A |
multiple interactions |
ISO |
enrasentan binds to and results in decreased activity of EDNRA protein |
CTD |
PMID:16219361 |
|
NCBI chr19:30,233,540...30,303,727
Ensembl chr19:30,233,571...30,297,049
|
|
G |
Ednrb |
endothelin receptor type B |
multiple interactions |
ISO |
enrasentan binds to and results in decreased activity of EDNRB protein |
CTD |
PMID:16219361 |
|
NCBI chr15:80,640,839...80,672,115
Ensembl chr15:80,643,043...80,672,115
|
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
decreases activity multiple interactions |
ISO |
Losartan results in decreased activity of ABCB11 protein Losartan inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid] |
CTD |
PMID:23956101 PMID:24014644 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Ace |
angiotensin I converting enzyme |
multiple interactions decreases expression |
ISO EXP |
Losartan inhibits the reaction [AGT protein results in increased expression of ACE mRNA]; Losartan inhibits the reaction [AGT protein results in increased expression of ACE protein]; Losartan inhibits the reaction [Oxygen deficiency results in increased expression of ACE protein]; Losartan inhibits the reaction [Silicon Dioxide results in increased expression of ACE mRNA]; Losartan inhibits the reaction [Silicon Dioxide results in increased expression of ACE protein] Losartan results in decreased expression of ACE protein |
CTD |
PMID:25511041 PMID:25655897 PMID:28091615 PMID:28578904 PMID:33007385 |
|
NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
|
|
G |
Ace2 |
angiotensin I converting enzyme 2 |
multiple interactions increases activity increases expression |
EXP ISO |
Losartan inhibits the reaction [AGT protein results in decreased expression of ACE2 mRNA]; Losartan inhibits the reaction [AGT protein results in decreased expression of ACE2 protein]; Losartan inhibits the reaction [Tobacco Smoke Pollution results in decreased expression of ACE2 protein] Losartan results in increased activity of ACE2 protein Losartan results in increased expression of ACE2 protein Losartan results in increased expression of ACE2 mRNA; Losartan results in increased expression of ACE2 protein Losartan inhibits the reaction [AGT protein results in decreased expression of ACE2 mRNA]; Losartan inhibits the reaction [AGT protein results in decreased expression of ACE2 protein]; Losartan inhibits the reaction [Oxygen deficiency results in decreased expression of ACE2 protein]; Losartan inhibits the reaction [Silicon Dioxide results in decreased expression of ACE2 protein] |
CTD |
PMID:15897343 PMID:16176966 PMID:16221218 PMID:20178811 PMID:22009550 PMID:25511041 PMID:25655897 PMID:28091615 PMID:33007385 More...
|
|
NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
decreases expression multiple interactions |
EXP ISO |
Losartan results in decreased expression of ACTA2 mRNA; Losartan results in decreased expression of ACTA2 protein Losartan inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]; Losartan inhibits the reaction [Silicon Dioxide results in increased expression of ACTA2 protein] |
CTD |
PMID:15100363 PMID:28091615 PMID:28578904 PMID:33007385 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Actg2 |
actin gamma 2, smooth muscle |
decreases expression |
EXP |
Losartan results in decreased expression of ACTG2 mRNA |
CTD |
PMID:15100363 |
|
NCBI chr 4:116,021,832...116,046,475
Ensembl chr 4:116,021,832...116,046,465
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
increases expression |
ISO |
Losartan results in increased expression of ADIPOQ mRNA |
CTD |
PMID:19730415 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
affects expression |
EXP |
Losartan affects the expression of ADRB2 protein |
CTD |
PMID:9260993 |
|
NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512
|
|
G |
Afp |
alpha-fetoprotein |
multiple interactions |
ISO |
Losartan inhibits the reaction [Diethylnitrosamine results in increased expression of AFP protein] |
CTD |
PMID:29859236 |
|
NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480
|
|
G |
Ager |
advanced glycosylation end product-specific receptor |
multiple interactions |
EXP |
Losartan inhibits the reaction [Glucose promotes the reaction [Linoleic Acid promotes the reaction [Azoxymethane results in increased expression of AGER protein]]]; Losartan inhibits the reaction [Linoleic Acid promotes the reaction [Glucose promotes the reaction [Azoxymethane results in increased expression of AGER protein]]] |
CTD |
PMID:22467055 |
|
NCBI chr20:4,148,150...4,151,361
Ensembl chr20:4,147,890...4,151,078
|
|
G |
Agt |
angiotensinogen |
multiple interactions increases secretion decreases activity decreases response to substance increases expression decreases expression |
ISO EXP |
[Losartan co-treated with ICG 001] inhibits the reaction [AGT protein results in decreased expression of NPHS2 protein]; [Losartan co-treated with ICG 001] inhibits the reaction [AGT protein results in increased expression of S100A4 protein]; [Losartan results in decreased activity of AGTR1 protein] which results in increased expression of AGT protein alternative form; ICG 001 promotes the reaction [Losartan inhibits the reaction [AGT protein results in increased expression of MMP7 protein]]; ICG 001 promotes the reaction [Losartan inhibits the reaction [AGT protein results in increased expression of SNAI1 protein]]; Losartan inhibits the reaction [[AGT protein modified form co-treated with Ascorbic Acid co-treated with Copper Sulfate] results in increased chemical synthesis of [4-hydroxy-2-nonenal binds to AGT protein modified form]]; Losartan inhibits the reaction [[AGT protein modified form co-treated with Ascorbic Acid co-treated with Copper Sulfate] results in increased chemical synthesis of [pyruvamide binds to AGT protein modified form]]; Losartan inhibits the reaction [AGT protein affects the localization of CTNNB1 protein]; Losartan inhibits the reaction [AGT protein modified form promotes the reaction [[Shiga Toxin 1 co-treated with TNF protein] results in increased activity of F3 protein]]; Losartan inhibits the reaction [AGT protein modified form results in decreased secretion of Nitric Oxide]; Losartan inhibits the reaction [AGT protein modified form results in increased expression of EDN1 protein]; Losartan inhibits the reaction [AGT protein results in decreased expression of CDH1 protein]; Losartan inhibits the reaction [AGT protein results in decreased expression of HMOX1 protein]; Losartan inhibits the reaction [AGT protein results in decreased expression of NFE2L2 protein]; Losartan inhibits the reaction [AGT protein results in increased abundance of Aldosterone]; Losartan inhibits the reaction [AGT protein results in increased expression of ACE protein]; Losartan inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]; Losartan inhibits the reaction [AGT protein results in increased expression of AGT protein]; Losartan inhibits the reaction [AGT protein results in increased expression of AGTR1A protein]; Losartan inhibits the reaction [AGT protein results in increased expression of and results in increased activity of CTNNB1 protein]; Losartan inhibits the reaction [AGT protein results in increased expression of CCL2 protein]; Losartan inhibits the reaction [AGT protein results in increased expression of COL3A1 protein]; Losartan inhibits the reaction [AGT protein results in increased expression of CTNNB1 mRNA]; Losartan inhibits the reaction [AGT protein results in increased expression of MMP7 protein]; Losartan inhibits the reaction [AGT protein results in increased expression of PTGS2 protein]; Losartan inhibits the reaction [AGT protein results in increased expression of REN protein]; Losartan inhibits the reaction [AGT protein results in increased expression of S100A4 protein]; Losartan inhibits the reaction [AGT protein results in increased expression of SNAI1 protein]; Losartan inhibits the reaction [AGT protein results in increased expression of TWIST1 protein]; Losartan inhibits the reaction [AGT protein results in increased expression of VIM protein]; Losartan inhibits the reaction [AGT protein results in increased expression of WNT1 mRNA]; Losartan inhibits the reaction [AGT protein results in increased expression of WNT1 protein]; Losartan inhibits the reaction [AGT protein results in increased secretion of ICAM1 protein]; Losartan promotes the reaction [AGT protein results in increased expression of VEGFA mRNA]; Losartan promotes the reaction [AGT protein results in increased secretion of VEGFA protein]; Losartan promotes the reaction [ICG 001 inhibits the reaction [AGT protein results in increased expression of COL3A1 protein]]; Losartan promotes the reaction [ICG 001 inhibits the reaction [AGT protein results in increased expression of MMP7 protein]]; Losartan promotes the reaction [ICG 001 inhibits the reaction [AGT protein results in increased expression of SNAI1 protein]] Losartan results in increased secretion of AGT protein; Losartan results in increased secretion of AGT protein alternative form [Losartan results in decreased activity of AGT protein] which results in decreased activity of TGFB1 protein; Losartan results in decreased activity of AGT protein Losartan results in decreased susceptibility to AGT protein modified form Losartan results in increased expression of AGT protein Losartan results in decreased activity of AGT protein; Losartan results in decreased activity of AGT protein modified form Losartan results in decreased expression of AGT protein; Losartan results in decreased expression of AGT protein alternative form; Losartan results in decreased expression of AGT protein modified form [Lisinopril co-treated with Losartan] results in increased expression of AGT mRNA; [Losartan co-treated with Carvedilol] results in decreased susceptibility to AGT protein modified form; Carvedilol inhibits the reaction [Losartan results in decreased susceptibility to AGT protein modified form]; Losartan inhibits the reaction [[AGT protein binds to and results in increased localization of AGTR1A protein] which results in increased expression of PTGS2 protein]; Losartan inhibits the reaction [[AGT protein binds to and results in increased localization of AGTR1A protein] which results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Losartan inhibits the reaction [[AGT protein binds to and results in increased localization of AGTR1A protein] which results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Losartan inhibits the reaction [[Phenylephrine results in increased expression of AGT protein] which results in increased activity of MMP2 protein]; Losartan inhibits the reaction [AGT protein affects the abundance of Cholesterol]; Losartan inhibits the reaction [AGT protein affects the localization of Calcium]; Losartan inhibits the reaction [AGT protein affects the localization of Lipids]; Losartan inhibits the reaction [AGT protein alternative form results in increased expression of PDGFA mRNA alternative form]; Losartan inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]]; Losartan inhibits the reaction [AGT protein modified form results in increased expression of BAX protein]; Losartan inhibits the reaction [AGT protein modified form results in increased expression of S1PR1 mRNA]; Losartan inhibits the reaction [AGT protein modified form results in increased expression of S1PR1 protein]; Losartan inhibits the reaction [AGT protein modified form results in increased phosphorylation of GSK3B protein]; Losartan inhibits the reaction [AGT protein modified form results in increased phosphorylation of MAPT protein]; Losartan inhibits the reaction [AGT protein results in decreased expression of ACE2 mRNA]; Losartan inhibits the reaction [AGT protein results in decreased expression of ACE2 protein]; Losartan inhibits the reaction [AGT protein results in decreased expression of CPT1A mRNA]; Losartan inhibits the reaction [AGT protein results in increased abundance of Fatty Acids, Nonesterified]; Losartan inhibits the reaction [AGT protein results in increased abundance of Glycerol]; Losartan inhibits the reaction [AGT protein results in increased abundance of Norepinephrine]; Losartan inhibits the reaction [AGT protein results in increased abundance of Triglycerides]; Losartan inhibits the reaction [AGT protein results in increased activity of CREB1 protein]; Losartan inhibits the reaction [AGT protein results in increased cleavage of SREBF1 protein]; Losartan inhibits the reaction [AGT protein results in increased expression of ATP1A1 mRNA]; Losartan inhibits the reaction [AGT protein results in increased expression of ENG mRNA]; Losartan inhibits the reaction [AGT protein results in increased expression of ENG protein]; Losartan inhibits the reaction [AGT protein results in increased expression of FASN mRNA]; Losartan inhibits the reaction [AGT protein results in increased expression of FOS protein]; Losartan inhibits the reaction [AGT protein results in increased expression of HMGCR mRNA]; Losartan inhibits the reaction [AGT protein results in increased expression of HSPA5 protein]; Losartan inhibits the reaction [AGT protein results in increased expression of MYLK protein]; Losartan inhibits the reaction [AGT protein results in increased expression of PARP1 protein]; Losartan inhibits the reaction [AGT protein results in increased expression of PDGFB mRNA]; Losartan inhibits the reaction [AGT protein results in increased expression of PDGFD mRNA]; Losartan inhibits the reaction [AGT protein results in increased expression of PDGFRB mRNA]; Losartan inhibits the reaction [AGT protein results in increased expression of POSTN mRNA]; Losartan inhibits the reaction [AGT protein results in increased expression of PPARA mRNA]; Losartan inhibits the reaction [AGT protein results in increased expression of PPARG mRNA]; Losartan inhibits the reaction [AGT protein results in increased expression of PPARGC1A mRNA]; Losartan inhibits the reaction [AGT protein results in increased expression of PTHLH mRNA]; Losartan inhibits the reaction [AGT protein results in increased expression of PTHLH protein]; Losartan inhibits the reaction [AGT protein results in increased expression of REG3G mRNA]; Losartan inhibits the reaction [AGT protein results in increased expression of SREBF1 mRNA]; Losartan inhibits the reaction [AGT protein results in increased expression of TSC22D1 mRNA]; Losartan inhibits the reaction [AGT protein results in increased expression of UCP2 mRNA]; Losartan inhibits the reaction [AGT protein results in increased expression of UCP3 mRNA]; Losartan inhibits the reaction [AGT protein results in increased phosphorylation of EIF2S1 protein]; Losartan inhibits the reaction [AGT protein results in increased phosphorylation of MAPK1 protein]; Losartan inhibits the reaction [AGT protein results in increased phosphorylation of MAPK3 protein]; Losartan inhibits the reaction [AGT protein results in increased phosphorylation of SREBF1 protein]; Losartan inhibits the reaction [AGT protein results in increased secretion of COL3A1 protein]; Losartan inhibits the reaction [AGT protein results in increased secretion of PRL protein]; Losartan inhibits the reaction [Carvedilol results in decreased susceptibility to AGT protein modified form]; Losartan inhibits the reaction [Ethanol results in increased secretion of AGT protein alternative form]; Losartan inhibits the reaction [Folic Acid results in increased localization of [AGT protein binds to AGTR1A protein]]; Losartan inhibits the reaction [Folic Acid results in increased localization of AGT protein]; Losartan inhibits the reaction [Isoproterenol results in increased expression of AGT protein]; Losartan inhibits the reaction [Sodium Chloride results in increased expression of AGT protein]; Losartan inhibits the reaction [Tobacco Smoke Pollution results in increased expression of AGT protein]; Losartan promotes the reaction [AGTR2 protein binds to AGT protein]; Losartan promotes the reaction [Isoproterenol results in increased expression of AGT protein] Losartan inhibits the reaction [AGT protein affects the localization of CTNNB1 protein]; Losartan inhibits the reaction [AGT protein results in decreased abundance of angiotensin I (1-7)]; Losartan inhibits the reaction [AGT protein results in decreased expression of ACE2 mRNA]; Losartan inhibits the reaction [AGT protein results in decreased expression of ACE2 protein]; Losartan inhibits the reaction [AGT protein results in decreased expression of CDH1 protein]; Losartan inhibits the reaction [AGT protein results in decreased expression of MAS1 protein]; Losartan inhibits the reaction [AGT protein results in decreased expression of NFE2L2 protein]; Losartan inhibits the reaction [AGT protein results in decreased expression of NPHS1 protein]; Losartan inhibits the reaction [AGT protein results in decreased expression of PODXL protein]; Losartan inhibits the reaction [AGT protein results in decreased expression of WT1 protein]; Losartan inhibits the reaction [AGT protein results in increased activity of PARP1 protein]; Losartan inhibits the reaction [AGT protein results in increased expression of ACE mRNA]; Losartan inhibits the reaction [AGT protein results in increased expression of ACE protein]; Losartan inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]; Losartan inhibits the reaction [AGT protein results in increased expression of AGT protein]; Losartan inhibits the reaction [AGT protein results in increased expression of AGTR1 protein]; Losartan inhibits the reaction [AGT protein results in increased expression of AGTR1A protein]; Losartan inhibits the reaction [AGT protein results in increased expression of AKT2 protein]; Losartan inhibits the reaction [AGT protein results in increased expression of CCL2 protein]; Losartan inhibits the reaction [AGT protein results in increased expression of COL3A1 protein]; Losartan inhibits the reaction [AGT protein results in increased expression of CTNNB1 mRNA]; Losartan inhibits the reaction [AGT protein results in increased expression of CTNNB1 protein]; Losartan inhibits the reaction [AGT protein results in increased expression of DES protein]; Losartan inhibits the reaction [AGT protein results in increased expression of FOS protein]; Losartan inhibits the reaction [AGT protein results in increased expression of MMP7 protein]; Losartan inhibits the reaction [AGT protein results in increased expression of PTGS2 protein]; Losartan inhibits the reaction [AGT protein results in increased expression of RELA protein]; Losartan inhibits the reaction [AGT protein results in increased expression of REN1 protein]; Losartan inhibits the reaction [AGT protein results in increased expression of SOD3 protein]; Losartan inhibits the reaction [AGT protein results in increased expression of TWIST1 protein]; Losartan inhibits the reaction [AGT protein results in increased expression of VIM protein]; Losartan inhibits the reaction [AGT protein results in increased expression of WNT1 mRNA]; Losartan inhibits the reaction [AGT protein results in increased expression of WNT1 protein]; Losartan inhibits the reaction [Silicon Dioxide results in decreased expression of AGT protein alternative form]; Losartan inhibits the reaction [Silicon Dioxide results in increased expression of AGT protein] |
CTD |
PMID:1387008 PMID:7965263 PMID:8403307 PMID:8952583 PMID:9124547 PMID:9176287 PMID:9519251 PMID:9533614 PMID:10082498 PMID:10400907 PMID:10517737 PMID:11463773 PMID:11709406 PMID:11967826 PMID:12084390 PMID:12411096 PMID:12431451 PMID:12692751 PMID:14630723 PMID:14722030 PMID:15121739 PMID:15213268 PMID:15361886 PMID:15502880 PMID:15528393 PMID:15539634 PMID:15728788 PMID:15741261 PMID:15897343 PMID:16176966 PMID:16221218 PMID:16251426 PMID:16539842 PMID:17043664 PMID:17224469 PMID:17481528 PMID:17666345 PMID:18060435 PMID:18267125 PMID:18511912 PMID:19109942 PMID:19183357 PMID:19298698 PMID:20178811 PMID:20232302 PMID:21047287 PMID:21152098 PMID:21166975 PMID:21613610 PMID:21613793 PMID:22982071 PMID:22982863 PMID:23300732 PMID:23875703 PMID:25398788 PMID:26464165 PMID:27798352 PMID:28578904 PMID:29609002 PMID:31144504 PMID:33007385 More...
|
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Agtr1a |
angiotensin II receptor, type 1a |
multiple interactions decreases expression increases expression decreases activity |
ISO EXP |
[Losartan results in decreased activity of AGTR1 protein] which results in decreased abundance of Aldosterone; [Losartan results in decreased activity of AGTR1 protein] which results in increased expression of AGT protein alternative form; [Losartan results in decreased activity of AGTR1 protein] which results in increased expression of REN protein; Losartan binds to and results in decreased activity of AGTR1 protein; Losartan inhibits the reaction [AGT protein results in increased expression of AGTR1A protein] Losartan binds to and results in decreased activity of AGTR1A protein; Losartan inhibits the reaction [AGT protein results in increased expression of AGTR1 protein]; Losartan inhibits the reaction [AGT protein results in increased expression of AGTR1A protein]; Losartan inhibits the reaction [Hydrogen Peroxide results in increased expression of AGTR1A mRNA]; Losartan inhibits the reaction [Oxygen deficiency results in increased expression of AGTR1 protein]; Losartan inhibits the reaction [Silicon Dioxide results in increased expression of AGTR1 protein] Losartan results in decreased expression of AGTR1 protein; Losartan results in decreased expression of AGTR1A mRNA; Losartan results in decreased expression of AGTR1A protein Losartan results in increased expression of AGTR1 mRNA; Losartan results in increased expression of AGTR1A mRNA [Cilazapril co-treated with Losartan] promotes the reaction [Doxorubicin results in increased expression of AGTR1 mRNA]; Losartan binds to and results in decreased activity of AGTR1 protein; Losartan binds to and results in decreased activity of AGTR1A protein; Losartan inhibits the reaction [[AGT protein binds to and results in increased localization of AGTR1A protein] which results in increased expression of PTGS2 protein]; Losartan inhibits the reaction [[AGT protein binds to and results in increased localization of AGTR1A protein] which results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Losartan inhibits the reaction [[AGT protein binds to and results in increased localization of AGTR1A protein] which results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Losartan inhibits the reaction [Carbon Tetrachloride results in increased expression of AGTR1A mRNA]; Losartan inhibits the reaction [Carbon Tetrachloride results in increased expression of AGTR1A protein]; Losartan inhibits the reaction [Doxorubicin results in increased expression of AGTR1 mRNA]; Losartan inhibits the reaction [Doxorubicin results in increased expression of AGTR1 protein]; Losartan inhibits the reaction [Folic Acid results in increased localization of [AGT protein binds to AGTR1A protein]] |
CTD |
PMID:9124547 PMID:9533614 PMID:10821809 PMID:11893553 PMID:12930639 PMID:15157388 PMID:15331931 PMID:15528393 PMID:15728788 PMID:15807884 PMID:15809360 PMID:18267125 PMID:18300857 PMID:18765277 PMID:22306536 PMID:25511041 PMID:28091615 PMID:28578904 PMID:33007385 More...
|
|
NCBI chr17:34,173,446...34,226,892
Ensembl chr17:34,174,429...34,226,946
|
|
G |
Agtr2 |
angiotensin II receptor, type 2 |
multiple interactions increases expression decreases expression |
EXP ISO |
[Losartan co-treated with Cilazapril] inhibits the reaction [Doxorubicin results in decreased expression of AGTR2 mRNA]; Losartan inhibits the reaction [Doxorubicin results in decreased expression of AGTR2 mRNA]; Losartan promotes the reaction [AGTR2 protein binds to AGT protein] Losartan inhibits the reaction [Oxygen deficiency results in decreased expression of AGTR2 protein] Losartan results in increased expression of AGTR2 protein Losartan results in decreased expression of AGTR2 mRNA |
CTD |
PMID:9336375 PMID:11967826 PMID:15331931 PMID:18300857 PMID:25511041 |
|
NCBI chr X:112,119,673...112,124,060
Ensembl chr X:112,120,228...112,124,057
|
|
G |
Akt2 |
AKT serine/threonine kinase 2 |
multiple interactions |
ISO |
Losartan inhibits the reaction [AGT protein results in increased expression of AKT2 protein] |
CTD |
PMID:28578904 |
|
NCBI chr 1:82,877,228...82,933,828
Ensembl chr 1:82,883,547...82,933,817
|
|
G |
Alb |
albumin |
affects binding |
ISO |
Losartan binds to ALB protein; Losartan binds to ALB protein modified form |
CTD |
PMID:27470663 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Alox15 |
arachidonate 15-lipoxygenase |
decreases expression |
EXP |
Losartan results in decreased expression of ALOX15 mRNA; Losartan results in decreased expression of ALOX15 protein |
CTD |
PMID:15100363 |
|
NCBI chr10:55,060,169...55,068,885
Ensembl chr10:55,060,412...55,068,874
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
decreases expression |
EXP |
Losartan results in decreased expression of ALOX5 protein |
CTD |
PMID:21377515 |
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
Ambp |
alpha-1-microglobulin/bikunin precursor |
decreases expression multiple interactions |
ISO |
Losartan results in decreased expression of AMBP protein benazepril promotes the reaction [Losartan results in decreased expression of AMBP protein]; Losartan promotes the reaction [benazepril results in decreased expression of AMBP protein] |
CTD |
PMID:16303729 |
|
NCBI chr 5:76,568,094...76,578,416
Ensembl chr 5:76,568,094...76,578,331
|
|
G |
Atp1a1 |
ATPase Na+/K+ transporting subunit alpha 1 |
multiple interactions |
EXP |
Losartan inhibits the reaction [AGT protein results in increased expression of ATP1A1 mRNA] |
CTD |
PMID:14630723 |
|
NCBI chr 2:189,020,722...189,048,826
Ensembl chr 2:189,020,722...189,048,837
|
|
G |
Atp1a2 |
ATPase Na+/K+ transporting subunit alpha 2 |
increases expression |
EXP |
Losartan results in increased expression of ATP1A2 mRNA; Losartan results in increased expression of ATP1A2 protein |
CTD |
PMID:18418421 |
|
NCBI chr13:84,729,597...84,754,544
Ensembl chr13:84,729,601...84,754,544
|
|
G |
Atp1a3 |
ATPase Na+/K+ transporting subunit alpha 3 |
decreases expression |
EXP |
Losartan results in decreased expression of ATP1A3 mRNA; Losartan results in decreased expression of ATP1A3 protein |
CTD |
PMID:18418421 |
|
NCBI chr 1:80,572,790...80,601,936
Ensembl chr 1:80,572,796...80,601,918
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
multiple interactions |
EXP |
Losartan inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of BAK1 mRNA] |
CTD |
PMID:15502641 |
|
NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression decreases expression |
EXP |
Losartan inhibits the reaction [AGT protein modified form results in increased expression of BAX protein]; Losartan inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased expression of BAX mRNA] Losartan results in increased expression of BAX protein Losartan results in decreased expression of BAX mRNA |
CTD |
PMID:12623880 PMID:12845756 PMID:15502641 PMID:17784886 PMID:19298698 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions affects expression increases expression decreases expression |
EXP |
Losartan promotes the reaction [Trinitrobenzenesulfonic Acid results in decreased expression of BCL2 mRNA] Losartan affects the expression of BCL2 protein Losartan results in increased expression of BCL2 protein Losartan results in decreased expression of BCL2 protein |
CTD |
PMID:12623880 PMID:15502641 PMID:19298698 PMID:21153712 PMID:22000973 |
|
NCBI chr13:22,689,783...22,853,920
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
multiple interactions |
EXP |
Losartan affects the reaction [[Warfarin co-treated with Vitamin K 1] affects the expression of BMP2 mRNA]; Losartan affects the reaction [[Warfarin co-treated with Vitamin K 1] affects the expression of BMP2 protein] |
CTD |
PMID:27412937 |
|
NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397
|
|
G |
Camk2a |
calcium/calmodulin-dependent protein kinase II alpha |
multiple interactions |
ISO |
[KN 93 co-treated with Losartan] inhibits the reaction [bisphenol A results in increased phosphorylation of CAMK2A protein]; Losartan inhibits the reaction [bisphenol A results in increased phosphorylation of CAMK2A protein] |
CTD |
PMID:25103225 |
|
NCBI chr18:54,378,642...54,441,120
Ensembl chr18:54,378,784...54,438,994
|
|
G |
Casp3 |
caspase 3 |
increases cleavage decreases activity multiple interactions |
EXP |
Losartan results in increased cleavage of CASP3 protein Losartan results in decreased activity of CASP3 protein Losartan inhibits the reaction [AGT protein inhibits the reaction [Glycochenodeoxycholic Acid results in increased activity of CASP3 protein]] |
CTD |
PMID:12623880 PMID:23300732 PMID:23875703 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
decreases activity |
EXP |
Losartan results in decreased activity of CASP8 protein |
CTD |
PMID:23875703 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases cleavage |
EXP |
Losartan results in increased cleavage of CASP9 protein |
CTD |
PMID:12623880 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
decreases expression multiple interactions |
EXP |
Losartan results in decreased expression of CAT protein Losartan inhibits the reaction [Streptozocin results in decreased activity of CAT protein] |
CTD |
PMID:23875703 PMID:30958922 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions decreases expression |
EXP ISO |
Losartan inhibits the reaction [Estrogens deficiency results in increased expression of CCL2 protein]; Losartan inhibits the reaction [Ethylene Glycol results in increased expression of CCL2 protein] Losartan inhibits the reaction [AGT protein results in increased expression of CCL2 protein] Losartan results in decreased expression of CCL2 mRNA; Losartan results in decreased expression of CCL2 protein |
CTD |
PMID:10925121 PMID:16284884 PMID:17922026 PMID:19553526 PMID:28578904 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
multiple interactions |
EXP |
Losartan inhibits the reaction [Estrogens deficiency results in increased expression of CCL3 protein] |
CTD |
PMID:19553526 |
|
NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
EXP |
Losartan inhibits the reaction [Ethylene Glycol results in increased expression of CCL5 protein] |
CTD |
PMID:16284884 |
|
NCBI chr10:68,322,826...68,327,365
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
Losartan inhibits the reaction [Diethylnitrosamine results in increased expression of CCND1 mRNA] |
CTD |
PMID:29859236 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccr2 |
C-C motif chemokine receptor 2 |
decreases expression |
EXP |
Losartan results in decreased expression of CCR2 mRNA |
CTD |
PMID:17922026 |
|
NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100
|
|
G |
Cd36 |
CD36 molecule |
increases expression decreases expression multiple interactions |
ISO |
Losartan results in increased expression of CD36 mRNA Losartan results in decreased expression of CD36 mRNA Losartan promotes the reaction [[Dietary Fats co-treated with Cholesterol] results in increased expression of CD36 mRNA] T 0070907 inhibits the reaction [Losartan results in increased expression of CD36 mRNA] |
CTD |
PMID:18302760 PMID:22124178 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cd74 |
CD74 molecule |
decreases expression |
EXP |
Losartan results in decreased expression of CD74 mRNA |
CTD |
PMID:15100363 |
|
NCBI chr18:54,256,757...54,266,003
Ensembl chr18:54,256,778...54,266,003
|
|
G |
Cdh1 |
cadherin 1 |
multiple interactions |
ISO |
Losartan inhibits the reaction [AGT protein results in decreased expression of CDH1 protein] Losartan inhibits the reaction [AGT protein results in decreased expression of CDH1 protein]; Losartan inhibits the reaction [Silicon Dioxide results in decreased expression of CDH1 protein] |
CTD |
PMID:28578904 PMID:33007385 |
|
NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
ISO |
Losartan inhibits the reaction [KRAS protein mutant form results in increased expression of CDKN1A protein] |
CTD |
PMID:33380422 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
multiple interactions |
ISO |
Losartan inhibits the reaction [KRAS protein mutant form results in increased expression of CDKN2A protein] |
CTD |
PMID:33380422 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
decreases expression multiple interactions |
EXP ISO |
Losartan results in decreased expression of COL1A1 mRNA Losartan inhibits the reaction [Lipopolysaccharides results in increased expression of COL1A1 mRNA] |
CTD |
PMID:15100363 PMID:18300870 PMID:23585870 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
decreases expression multiple interactions |
EXP ISO |
Losartan results in decreased expression of COL3A1 mRNA Losartan inhibits the reaction [AGT protein results in increased expression of COL3A1 protein]; Losartan promotes the reaction [ICG 001 inhibits the reaction [AGT protein results in increased expression of COL3A1 protein]] Losartan inhibits the reaction [AGT protein results in increased expression of COL3A1 protein]; Losartan inhibits the reaction [Lipopolysaccharides results in increased expression of COL3A1 mRNA]; Losartan inhibits the reaction [Silicon Dioxide results in increased expression of COL3A1 protein] Losartan inhibits the reaction [AGT protein results in increased secretion of COL3A1 protein]; Losartan inhibits the reaction [Paraquat results in increased expression of COL3A1 protein] |
CTD |
PMID:15100363 PMID:16539842 PMID:23585870 PMID:25233898 PMID:28578904 PMID:33007385 More...
|
|
NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547
|
|
G |
Col4a1 |
collagen type IV alpha 1 chain |
decreases expression |
EXP |
Losartan results in decreased expression of COL4A1 mRNA |
CTD |
PMID:16191423 |
|
NCBI chr16:78,183,533...78,294,412
Ensembl chr16:78,183,533...78,294,412
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
multiple interactions |
EXP |
Losartan inhibits the reaction [AGT protein results in decreased expression of CPT1A mRNA] |
CTD |
PMID:19109942 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
EXP |
Losartan inhibits the reaction [AGT protein results in increased activity of CREB1 protein]; Losartan inhibits the reaction [Folic Acid results in increased activity of CREB1 protein] |
CTD |
PMID:15728788 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Ctnnb1 |
catenin beta 1 |
multiple interactions |
ISO |
Losartan inhibits the reaction [AGT protein affects the localization of CTNNB1 protein]; Losartan inhibits the reaction [AGT protein results in increased expression of CTNNB1 mRNA]; Losartan inhibits the reaction [AGT protein results in increased expression of CTNNB1 protein] Losartan inhibits the reaction [AGT protein affects the localization of CTNNB1 protein]; Losartan inhibits the reaction [AGT protein results in increased expression of and results in increased activity of CTNNB1 protein]; Losartan inhibits the reaction [AGT protein results in increased expression of CTNNB1 mRNA] |
CTD |
PMID:28578904 |
|
NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111
|
|
G |
Cubn |
cubilin |
multiple interactions |
EXP |
Losartan inhibits the reaction [Cadmium results in decreased expression of CUBN protein] |
CTD |
PMID:24093454 |
|
NCBI chr17:76,385,046...76,593,133
Ensembl chr17:76,385,060...76,593,231
|
|
G |
Cxcl1 |
C-X-C motif chemokine ligand 1 |
multiple interactions |
EXP |
Losartan inhibits the reaction [Estrogens deficiency results in increased expression of CXCL1 protein] |
CTD |
PMID:19553526 |
|
NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215
|
|
G |
Cycs |
cytochrome c, somatic |
increases expression |
EXP |
Losartan results in increased expression of CYCS protein |
CTD |
PMID:18971572 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases expression |
ISO |
Losartan results in increased expression of CYP1A1 mRNA |
CTD |
PMID:9860486 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Dcn |
decorin |
decreases expression |
EXP |
Losartan results in decreased expression of DCN mRNA |
CTD |
PMID:15100363 |
|
NCBI chr 7:32,281,252...32,321,291
Ensembl chr 7:32,281,252...32,321,270
|
|
G |
Des |
desmin |
multiple interactions |
ISO |
Losartan inhibits the reaction [AGT protein results in increased expression of DES protein] |
CTD |
PMID:28578904 |
|
NCBI chr 9:76,850,979...76,858,695
Ensembl chr 9:76,850,982...76,858,699
|
|
G |
Edn1 |
endothelin 1 |
decreases expression multiple interactions |
ISO EXP |
Losartan results in decreased expression of EDN1 protein Losartan results in decreased expression of EDN1 mRNA; Losartan results in decreased expression of EDN1 protein Losartan inhibits the reaction [Nitroglycerin results in increased expression of EDN1 protein] Losartan inhibits the reaction [AGT protein modified form results in increased expression of EDN1 protein] |
CTD |
PMID:11369837 PMID:12901495 PMID:16191423 PMID:17666345 PMID:18971572 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Ednra |
endothelin receptor type A |
multiple interactions decreases expression |
EXP |
Atorvastatin promotes the reaction [Losartan results in decreased expression of EDNRA mRNA]; Losartan promotes the reaction [Atorvastatin results in decreased expression of EDNRA mRNA] |
CTD |
PMID:23091284 |
|
NCBI chr19:30,233,540...30,303,727
Ensembl chr19:30,233,571...30,297,049
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
multiple interactions |
EXP |
Losartan inhibits the reaction [AGT protein results in increased phosphorylation of EIF2S1 protein] |
CTD |
PMID:25398788 |
|
NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
|
|
G |
Eln |
elastin |
decreases expression |
EXP |
Losartan results in decreased expression of ELN mRNA |
CTD |
PMID:15100363 |
|
NCBI chr12:21,968,544...22,011,929
Ensembl chr12:21,968,544...22,011,928
|
|
G |
Eng |
endoglin |
multiple interactions |
EXP |
Losartan inhibits the reaction [AGT protein results in increased expression of ENG mRNA]; Losartan inhibits the reaction [AGT protein results in increased expression of ENG protein] |
CTD |
PMID:15539634 |
|
NCBI chr 3:15,934,566...15,972,618
Ensembl chr 3:15,934,518...15,973,230
|
|
G |
F3 |
coagulation factor III, tissue factor |
decreases expression multiple interactions |
ISO |
Losartan results in decreased expression of F3 mRNA; Losartan results in decreased expression of F3 protein Losartan inhibits the reaction [[Shiga Toxin 1 co-treated with TNF protein] results in increased activity of F3 protein]; Losartan inhibits the reaction [AGT protein modified form promotes the reaction [[Shiga Toxin 1 co-treated with TNF protein] results in increased activity of F3 protein]] |
CTD |
PMID:18060435 PMID:22188725 |
|
NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
Faslg |
Fas ligand |
decreases expression |
EXP |
Losartan results in decreased expression of FASLG mRNA |
CTD |
PMID:10925121 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fasn |
fatty acid synthase |
multiple interactions |
EXP |
Losartan inhibits the reaction [AGT protein results in increased expression of FASN mRNA] |
CTD |
PMID:19109942 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Flt1 |
Fms related receptor tyrosine kinase 1 |
decreases expression |
ISO |
Losartan results in decreased expression of FLT1 mRNA; Losartan results in decreased expression of FLT1 protein |
CTD |
PMID:19771429 |
|
NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626
|
|
G |
Flt4 |
Fms related receptor tyrosine kinase 4 |
decreases expression |
ISO |
Losartan results in decreased expression of FLT4 mRNA |
CTD |
PMID:19771429 |
|
NCBI chr10:33,913,725...33,954,770
Ensembl chr10:33,913,608...33,954,770
|
|
G |
Fn1 |
fibronectin 1 |
decreases expression |
EXP |
Losartan results in decreased expression of FN1 mRNA; Losartan results in decreased expression of FN1 protein |
CTD |
PMID:16191423 |
|
NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO EXP |
Losartan inhibits the reaction [AGT protein results in increased expression of FOS protein]; Losartan inhibits the reaction [Furosemide results in increased expression of FOS protein]; Losartan inhibits the reaction [Polyethylene Glycols results in increased expression of FOS protein] |
CTD |
PMID:11463773 PMID:15528393 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Gja1 |
gap junction protein, alpha 1 |
increases expression |
EXP |
Losartan results in increased expression of GJA1 protein |
CTD |
PMID:18971572 |
|
NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP ISO |
Losartan inhibits the reaction [Carbon Tetrachloride results in increased activity of GPT protein] Losartan inhibits the reaction [Diethylnitrosamine results in increased activity of GPT protein] |
CTD |
PMID:15573910 PMID:29859236 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
EXP |
Losartan inhibits the reaction [AGT protein modified form results in increased phosphorylation of GSK3B protein] |
CTD |
PMID:22982863 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Havcr1 |
hepatitis A virus cellular receptor 1 |
multiple interactions |
EXP |
Losartan inhibits the reaction [Cadmium results in increased expression of HAVCR1] |
CTD |
PMID:24093454 |
|
NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions |
EXP |
Losartan inhibits the reaction [AGT protein results in increased expression of HMGCR mRNA] |
CTD |
PMID:19109942 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases activity multiple interactions increases expression |
EXP ISO |
Losartan results in increased activity of HMOX1 protein Losartan inhibits the reaction [AGT protein results in decreased expression of HMOX1 protein] Losartan results in increased expression of HMOX1 mRNA cobaltiprotoporphyrin promotes the reaction [Losartan results in increased activity of HMOX1 protein]; cobaltiprotoporphyrin promotes the reaction [Losartan results in increased expression of HMOX1 mRNA] |
CTD |
PMID:19804535 PMID:28578904 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
EXP |
Losartan inhibits the reaction [AGT protein results in increased expression of HSPA5 protein] |
CTD |
PMID:25398788 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions decreases secretion |
ISO |
Losartan inhibits the reaction [AGT protein results in increased secretion of ICAM1 protein] Losartan results in decreased secretion of ICAM1 protein |
CTD |
PMID:10517737 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Ifng |
interferon gamma |
increases expression |
EXP |
Losartan results in increased expression of IFNG protein |
CTD |
PMID:23875703 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il10 |
interleukin 10 |
increases expression |
EXP |
Losartan results in increased expression of IL10 mRNA |
CTD |
PMID:18971572 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions decreases expression |
ISO EXP |
Losartan inhibits the reaction [IL1A protein results in increased expression of VEGFA mRNA]; Losartan inhibits the reaction [IL1A protein results in increased expression of VEGFA protein] Losartan results in decreased expression of IL1A protein |
CTD |
PMID:17299153 PMID:23875703 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il6 |
interleukin 6 |
decreases expression increases expression multiple interactions |
ISO EXP |
Losartan results in decreased expression of IL6 mRNA Losartan results in increased expression of IL6 protein Losartan inhibits the reaction [bisphenol A results in increased expression of IL6 mRNA]; Losartan inhibits the reaction [Ethylene Glycol results in increased expression of IL6 protein] |
CTD |
PMID:16284884 PMID:21479465 PMID:23875703 PMID:30677511 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Itga3 |
integrin subunit alpha 3 |
decreases expression |
EXP |
Losartan results in decreased expression of ITGA3 protein |
CTD |
PMID:15100363 |
|
NCBI chr10:79,990,160...80,022,206
Ensembl chr10:79,990,161...80,022,118
|
|
G |
Itga6 |
integrin subunit alpha 6 |
decreases expression |
EXP |
Losartan results in decreased expression of ITGA6 protein |
CTD |
PMID:15100363 |
|
NCBI chr 3:56,604,512...56,689,428
Ensembl chr 3:56,617,268...56,689,428
|
|
G |
Jak2 |
Janus kinase 2 |
multiple interactions |
ISO |
losartan inhibits the reaction [Angiotensin II increases phosphorylation of JAK2 protein in liver] |
RGD |
PMID:22613986 |
RGD:127285667 |
NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189
|
|
G |
Kdr |
kinase insert domain receptor |
multiple interactions |
EXP |
Losartan inhibits the reaction [Cyclosporine results in increased expression of KDR mRNA] |
CTD |
PMID:12110003 |
|
NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018
|
|
G |
Kras |
KRAS proto-oncogene, GTPase |
multiple interactions |
ISO |
Losartan inhibits the reaction [KRAS protein mutant form results in increased expression of CDKN1A protein]; Losartan inhibits the reaction [KRAS protein mutant form results in increased expression of CDKN2A protein] |
CTD |
PMID:33380422 |
|
NCBI chr 4:178,185,418...178,218,484
|
|
G |
Lox |
lysyl oxidase |
decreases expression |
EXP |
Losartan results in decreased expression of LOX mRNA |
CTD |
PMID:15100363 |
|
NCBI chr18:45,964,311...46,041,477
Ensembl chr18:45,967,343...46,041,477
|
|
G |
Lum |
lumican |
decreases expression |
EXP |
Losartan results in decreased expression of LUM mRNA |
CTD |
PMID:15100363 |
|
NCBI chr 7:32,358,990...32,365,794
Ensembl chr 7:32,358,614...32,365,793
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation increases activity |
EXP ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Losartan results in increased phosphorylation of MAPK1 protein]; Losartan inhibits the reaction [[AGT protein binds to and results in increased localization of AGTR1A protein] which results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Losartan inhibits the reaction [AGT protein results in increased phosphorylation of MAPK1 protein] Losartan results in increased activity of MAPK1 protein Losartan inhibits the reaction [Particulate Matter results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:11711055 PMID:16079071 PMID:18267125 PMID:18511912 PMID:20056918 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
decreases expression |
EXP |
Losartan results in decreased expression of MAPK14 protein |
CTD |
PMID:28091615 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation increases activity |
ISO EXP |
Losartan inhibits the reaction [Particulate Matter results in increased phosphorylation of MAPK3 protein] Losartan results in increased phosphorylation of MAPK3 protein Losartan results in increased activity of MAPK3 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Losartan results in increased phosphorylation of MAPK3 protein]; Losartan inhibits the reaction [[AGT protein binds to and results in increased localization of AGTR1A protein] which results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Losartan inhibits the reaction [AGT protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:11711055 PMID:16079071 PMID:18267125 PMID:18511912 PMID:20056918 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapt |
microtubule-associated protein tau |
multiple interactions |
EXP |
Losartan inhibits the reaction [AGT protein modified form results in increased phosphorylation of MAPT protein] |
CTD |
PMID:22982863 |
|
NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129
|
|
G |
Mas1 |
MAS1 proto-oncogene, G protein-coupled receptor |
multiple interactions |
ISO |
Losartan inhibits the reaction [AGT protein results in decreased expression of MAS1 protein]; Losartan inhibits the reaction [Silicon Dioxide results in decreased expression of MAS1 protein] |
CTD |
PMID:33007385 |
|
NCBI chr 1:47,879,956...47,911,500
Ensembl chr 1:47,880,309...47,911,709
|
|
G |
Mgp |
matrix Gla protein |
decreases expression |
EXP |
Losartan results in decreased expression of MGP mRNA |
CTD |
PMID:15100363 |
|
NCBI chr 4:169,766,290...169,769,612
Ensembl chr 4:169,766,279...169,769,667
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions |
EXP ISO |
Losartan inhibits the reaction [[Phenylephrine results in increased expression of AGT protein] which results in increased activity of MMP2 protein]; Losartan inhibits the reaction [Carbon Tetrachloride results in increased activity of MMP2 protein] Losartan inhibits the reaction [Diethylnitrosamine results in increased expression of MMP2 protein]; Losartan inhibits the reaction [Lipopolysaccharides results in increased expression of MMP2 mRNA] |
CTD |
PMID:12930639 PMID:16251426 PMID:23585870 PMID:29859236 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp23 |
matrix metallopeptidase 23 |
decreases expression |
EXP |
Losartan results in decreased expression of MMP23 mRNA |
CTD |
PMID:15100363 |
|
NCBI chr 5:166,239,643...166,242,734
Ensembl chr 5:166,239,644...166,242,433
|
|
G |
Mmp7 |
matrix metallopeptidase 7 |
multiple interactions |
ISO |
ICG 001 promotes the reaction [Losartan inhibits the reaction [AGT protein results in increased expression of MMP7 protein]]; Losartan inhibits the reaction [AGT protein results in increased expression of MMP7 protein]; Losartan promotes the reaction [ICG 001 inhibits the reaction [AGT protein results in increased expression of MMP7 protein]] |
CTD |
PMID:28578904 |
|
NCBI chr 8:4,848,186...4,855,908
Ensembl chr 8:4,848,186...4,855,902
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
decreases expression multiple interactions |
EXP ISO |
Losartan results in decreased expression of MMP9 mRNA Losartan inhibits the reaction [Paraquat results in increased expression of MMP9 mRNA] Losartan inhibits the reaction [Lipopolysaccharides results in increased expression of MMP9 mRNA] |
CTD |
PMID:18971572 PMID:23585870 PMID:25233898 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
affects expression |
EXP |
Losartan affects the expression of MYC protein |
CTD |
PMID:22000973 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Myh11 |
myosin heavy chain 11 |
decreases expression |
EXP |
Losartan results in decreased expression of MYH11 mRNA |
CTD |
PMID:15100363 |
|
NCBI chr10:743,364...838,459
Ensembl chr10:743,685...838,459
|
|
G |
Myh6 |
myosin heavy chain 6 |
multiple interactions |
EXP |
Losartan inhibits the reaction [Streptozocin results in decreased expression of MYH6 mRNA]; Losartan inhibits the reaction [Streptozocin results in decreased expression of MYH6 protein] |
CTD |
PMID:15362513 |
|
NCBI chr15:28,418,120...28,442,316
Ensembl chr15:28,417,616...28,441,720
|
|
G |
Myh7 |
myosin heavy chain 7 |
multiple interactions |
EXP |
Losartan inhibits the reaction [Streptozocin results in increased expression of MYH7 mRNA]; Losartan inhibits the reaction [Streptozocin results in increased expression of MYH7 protein] |
CTD |
PMID:15362513 |
|
NCBI chr15:28,446,550...28,469,888
Ensembl chr15:28,446,550...28,468,217
|
|
G |
Mylk |
myosin light chain kinase |
multiple interactions |
EXP |
Losartan inhibits the reaction [AGT protein results in increased expression of MYLK protein] |
CTD |
PMID:18511912 |
|
NCBI chr11:65,783,008...66,030,239
Ensembl chr11:65,783,008...66,030,261
|
|
G |
Ncf1 |
neutrophil cytosolic factor 1 |
multiple interactions |
ISO EXP |
Losartan inhibits the reaction [Hydrogen Peroxide results in increased expression of NCF1 mRNA] Losartan inhibits the reaction [Ethanol affects the localization of NCF1 protein] |
CTD |
PMID:22306536 PMID:22497828 PMID:22982071 |
|
NCBI chr12:22,485,382...22,494,647
Ensembl chr12:22,485,451...22,494,646
|
|
G |
Ndst1 |
N-deacetylase and N-sulfotransferase 1 |
multiple interactions |
EXP |
Losartan inhibits the reaction [Streptozocin results in decreased expression of NDST1 protein] |
CTD |
PMID:15793251 |
|
NCBI chr18:54,136,887...54,199,545
Ensembl chr18:54,140,779...54,178,191
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
decreases expression multiple interactions |
EXP ISO |
Losartan results in decreased expression of NFE2L2 mRNA Losartan inhibits the reaction [AGT protein results in decreased expression of NFE2L2 protein] |
CTD |
PMID:18765277 PMID:28578904 |
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
EXP ISO |
Losartan inhibits the reaction [Ethylene Glycol results in increased expression of NFKB1 protein] Losartan inhibits the reaction [Diethylnitrosamine results in decreased expression of NFKB1 protein] |
CTD |
PMID:16284884 PMID:29859236 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nos1 |
nitric oxide synthase 1 |
increases phosphorylation multiple interactions |
EXP |
Losartan results in increased phosphorylation of NOS1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Losartan results in increased phosphorylation of NOS1 protein] |
CTD |
PMID:20056918 |
|
NCBI chr12:38,615,111...38,795,492
Ensembl chr12:38,626,714...38,710,945
|
|
G |
Nos2 |
nitric oxide synthase 2 |
affects expression decreases expression increases expression |
EXP |
Losartan affects the expression of NOS2 mRNA Losartan results in decreased expression of NOS2 mRNA; Losartan results in decreased expression of NOS2 protein Losartan results in increased expression of NOS2 protein |
CTD |
PMID:12198324 PMID:16191423 PMID:18390819 PMID:21377515 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nos3 |
nitric oxide synthase 3 |
affects expression increases expression multiple interactions increases phosphorylation |
EXP |
Losartan affects the expression of NOS3 mRNA Losartan results in increased expression of NOS3 mRNA [Losartan co-treated with Atorvastatin] results in increased expression of NOS3 mRNA; Losartan inhibits the reaction [Sodium Chloride results in decreased expression of NOS3 protein] Losartan results in increased phosphorylation of NOS3 protein |
CTD |
PMID:12198324 PMID:18390819 PMID:18971572 PMID:20232302 PMID:23091284 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Nphs1 |
NPHS1 adhesion molecule, nephrin |
multiple interactions |
ISO |
Losartan inhibits the reaction [AGT protein results in decreased expression of NPHS1 protein] |
CTD |
PMID:28578904 |
|
NCBI chr 1:85,720,812...85,749,079
Ensembl chr 1:85,720,812...85,749,078
|
|
G |
Nphs2 |
NPHS2 stomatin family member, podocin |
multiple interactions |
ISO |
[Losartan co-treated with ICG 001] inhibits the reaction [AGT protein results in decreased expression of NPHS2 protein] |
CTD |
PMID:28578904 |
|
NCBI chr13:68,448,720...68,461,312
Ensembl chr13:68,448,926...68,461,313
|
|
G |
Nppa |
natriuretic peptide A |
multiple interactions decreases expression |
EXP |
Losartan inhibits the reaction [Nitric Oxide deficiency results in increased expression of NPPA mRNA] Losartan results in decreased expression of NPPA protein |
CTD |
PMID:12198334 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Nppb |
natriuretic peptide B |
multiple interactions decreases expression |
EXP |
[Atenolol co-treated with Losartan co-treated with Doxazosin] results in decreased expression of NPPB mRNA; [Losartan co-treated with Doxazosin] results in decreased expression of NPPB mRNA; [Losartan co-treated with Nifedipine] results in decreased expression of NPPB mRNA; Losartan inhibits the reaction [Nitric Oxide deficiency results in increased expression of NPPB mRNA] Losartan results in decreased expression of NPPB mRNA; Losartan results in decreased expression of NPPB protein |
CTD |
PMID:12198334 PMID:15969258 PMID:17666919 |
|
NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168
|
|
G |
Npr1 |
natriuretic peptide receptor 1 |
affects response to substance |
ISO |
NPR1 protein mutant form affects the susceptibility to Losartan |
CTD |
PMID:20881240 |
|
NCBI chr 2:175,934,181...175,950,118
Ensembl chr 2:175,934,181...175,949,505
|
|
G |
Nr1h3 |
nuclear receptor subfamily 1, group H, member 3 |
increases expression |
EXP |
Losartan results in increased expression of NR1H3 protein |
CTD |
PMID:28091615 |
|
NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722
|
|
G |
Nrf1 |
nuclear respiratory factor 1 |
increases expression |
EXP |
Losartan results in increased expression of NRF1 mRNA |
CTD |
PMID:18765277 |
|
NCBI chr 4:58,664,932...58,772,328
Ensembl chr 4:58,664,957...58,825,328
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
EXP ISO |
Losartan inhibits the reaction [AGT protein results in increased expression of PARP1 protein] Losartan inhibits the reaction [AGT protein results in increased activity of PARP1 protein] |
CTD |
PMID:15502880 PMID:21613793 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pdgfa |
platelet derived growth factor subunit A |
multiple interactions |
EXP |
Losartan inhibits the reaction [AGT protein alternative form results in increased expression of PDGFA mRNA alternative form] |
CTD |
PMID:12431451 |
|
NCBI chr12:15,645,549...15,667,056
Ensembl chr12:15,645,541...15,666,497
|
|
G |
Pdgfb |
platelet derived growth factor subunit B |
multiple interactions |
EXP |
Losartan inhibits the reaction [AGT protein results in increased expression of PDGFB mRNA]; Losartan inhibits the reaction [Carbon Tetrachloride results in increased expression of PDGFB protein] |
CTD |
PMID:12930639 PMID:17043664 |
|
NCBI chr 7:111,539,444...111,557,984
Ensembl chr 7:111,540,345...111,557,984
|
|
G |
Pdgfd |
platelet derived growth factor D |
multiple interactions |
EXP |
Losartan inhibits the reaction [AGT protein results in increased expression of PDGFD mRNA] |
CTD |
PMID:17043664 |
|
NCBI chr 8:3,488,448...3,722,395
Ensembl chr 8:3,488,423...3,722,395
|
|
G |
Pdgfrb |
platelet derived growth factor receptor beta |
multiple interactions |
EXP |
Losartan inhibits the reaction [AGT protein results in increased expression of PDGFRB mRNA] |
CTD |
PMID:17043664 |
|
NCBI chr18:54,500,002...54,538,843
Ensembl chr18:54,499,964...54,538,843
|
|
G |
Pdlim3 |
PDZ and LIM domain 3 |
decreases expression |
EXP |
Losartan results in decreased expression of PDLIM3 mRNA |
CTD |
PMID:15100363 |
|
NCBI chr16:46,352,460...46,383,680
Ensembl chr16:46,352,467...46,383,657
|
|
G |
Pecam1 |
platelet and endothelial cell adhesion molecule 1 |
decreases expression |
ISO |
Losartan results in decreased expression of PECAM1 mRNA |
CTD |
PMID:19771429 |
|
NCBI chr10:91,590,521...91,652,279
Ensembl chr10:91,590,521...91,652,116
|
|
G |
Plat |
plasminogen activator, tissue type |
decreases expression |
EXP |
Losartan results in decreased expression of PLAT mRNA |
CTD |
PMID:15100363 |
|
NCBI chr16:69,240,582...69,265,177
Ensembl chr16:69,240,585...69,268,223
|
|
G |
Podxl |
podocalyxin-like |
multiple interactions |
ISO |
Losartan inhibits the reaction [AGT protein results in decreased expression of PODXL protein] |
CTD |
PMID:28578904 |
|
NCBI chr 4:60,135,124...60,181,829
Ensembl chr 4:60,135,109...60,181,899
|
|
G |
Postn |
periostin |
multiple interactions decreases expression |
EXP ISO |
Losartan inhibits the reaction [AGT protein results in increased expression of POSTN mRNA] Losartan results in decreased expression of POSTN mRNA |
CTD |
PMID:15121739 PMID:21641384 |
|
NCBI chr 2:138,527,714...138,559,098
Ensembl chr 2:138,527,696...138,559,099
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
EXP |
Losartan inhibits the reaction [AGT protein results in increased expression of PPARA mRNA] |
CTD |
PMID:19109942 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
EXP ISO |
Losartan inhibits the reaction [AGT protein results in increased expression of PPARG mRNA] Losartan inhibits the reaction [[Dietary Fats co-treated with Cholesterol] results in increased expression of PPARG mRNA] |
CTD |
PMID:18302760 PMID:19109942 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions increases expression |
EXP |
Losartan inhibits the reaction [AGT protein results in increased expression of PPARGC1A mRNA] Losartan results in increased expression of PPARGC1A mRNA |
CTD |
PMID:18765277 PMID:18971572 PMID:19109942 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Prkcb |
protein kinase C, beta |
multiple interactions |
EXP |
Losartan inhibits the reaction [Ethanol results in increased expression of PRKCB protein] |
CTD |
PMID:22497828 |
|
NCBI chr 1:176,832,173...177,163,539
Ensembl chr 1:176,832,226...177,163,536
|
|
G |
Prl |
prolactin |
multiple interactions |
EXP |
Losartan inhibits the reaction [AGT protein results in increased secretion of PRL protein] |
CTD |
PMID:14722030 |
|
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions decreases expression |
EXP ISO |
Losartan inhibits the reaction [[AGT protein binds to and results in increased localization of AGTR1A protein] which results in increased expression of PTGS2 protein]; Losartan inhibits the reaction [Phenylephrine results in increased expression of PTGS2 mRNA]; Losartan inhibits the reaction [Phenylephrine results in increased expression of PTGS2 protein] Losartan inhibits the reaction [AGT protein results in increased expression of PTGS2 protein] Losartan results in decreased expression of PTGS2 mRNA; Losartan results in decreased expression of PTGS2 protein |
CTD |
PMID:17244722 PMID:18267125 PMID:21377515 PMID:28578904 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Pth1r |
parathyroid hormone 1 receptor |
multiple interactions |
EXP |
Losartan inhibits the reaction [Folic Acid results in decreased expression of PTH1R protein]; Losartan inhibits the reaction [Gentamicins results in decreased expression of PTH1R protein] |
CTD |
PMID:15728788 |
|
NCBI chr 8:110,693,910...110,725,458
Ensembl chr 8:110,697,485...110,719,729
|
|
G |
Pthlh |
parathyroid hormone-like hormone |
multiple interactions |
EXP |
Losartan inhibits the reaction [AGT protein results in increased expression of PTHLH mRNA]; Losartan inhibits the reaction [AGT protein results in increased expression of PTHLH protein]; Losartan inhibits the reaction [Folic Acid results in increased expression of PTHLH mRNA]; Losartan inhibits the reaction [Folic Acid results in increased expression of PTHLH protein]; Losartan inhibits the reaction [Gentamicins results in increased expression of PTHLH protein] |
CTD |
PMID:15728788 |
|
NCBI chr 4:180,188,792...180,199,847
Ensembl chr 4:180,188,792...180,199,847
|
|
G |
Reg3g |
regenerating family member 3 gamma |
multiple interactions |
EXP |
Losartan inhibits the reaction [AGT protein results in increased expression of REG3G mRNA] |
CTD |
PMID:27798352 |
|
NCBI chr 4:110,922,805...110,927,803
Ensembl chr 4:110,924,168...110,926,723
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP ISO |
Losartan inhibits the reaction [Doxorubicin results in increased expression of RELA mRNA] Losartan inhibits the reaction [AGT protein results in increased expression of RELA protein]; Losartan inhibits the reaction [Diethylnitrosamine results in increased phosphorylation of RELA protein] |
CTD |
PMID:15157388 PMID:28578904 PMID:29859236 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Ren |
renin |
multiple interactions increases expression increases activity |
ISO EXP |
[Losartan results in decreased activity of AGTR1 protein] which results in increased expression of REN protein; Losartan inhibits the reaction [AGT protein results in increased expression of REN protein]; Losartan promotes the reaction [Hydrochlorothiazide results in increased expression of REN protein] Losartan inhibits the reaction [AGT protein results in increased expression of REN1 protein] Losartan results in increased expression of REN mRNA; Losartan results in increased expression of REN protein Losartan results in increased activity of REN protein [Lisinopril co-treated with Losartan] results in increased expression of REN mRNA; Losartan inhibits the reaction [Ethanol results in increased activity of REN protein]; Losartan promotes the reaction [Isoproterenol results in increased expression of REN protein] |
CTD |
PMID:1387008 PMID:7965263 PMID:8382237 PMID:8403307 PMID:9124547 PMID:9245700 PMID:9431853 PMID:9533614 PMID:11709406 PMID:12013499 PMID:12569265 PMID:16221218 PMID:22982071 PMID:28578904 More...
|
|
NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489
|
|
G |
RT1-Da |
RT1 class II, locus Da |
decreases expression |
EXP |
Losartan results in decreased expression of RT1-DA mRNA |
CTD |
PMID:15100363 |
|
NCBI chr20:4,513,464...4,518,457
Ensembl chr20:4,512,911...4,518,455
|
|
G |
RT1-S3 |
RT1 class Ib, locus S3 |
decreases expression |
EXP |
Losartan results in decreased expression of RT1-S3 mRNA |
CTD |
PMID:15100363 |
|
NCBI chr20:2,670,654...2,675,411
Ensembl chr20:2,670,709...2,675,411
|
|
G |
Runx2 |
RUNX family transcription factor 2 |
multiple interactions |
EXP |
Losartan affects the reaction [[Warfarin co-treated with Vitamin K 1] affects the expression of RUNX2 mRNA]; Losartan affects the reaction [[Warfarin co-treated with Vitamin K 1] affects the expression of RUNX2 protein] |
CTD |
PMID:27412937 |
|
NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167
|
|
G |
S100a4 |
S100 calcium-binding protein A4 |
multiple interactions |
ISO |
[Losartan co-treated with ICG 001] inhibits the reaction [AGT protein results in increased expression of S100A4 protein]; Losartan inhibits the reaction [AGT protein results in increased expression of S100A4 protein] |
CTD |
PMID:28578904 |
|
NCBI chr 2:176,090,951...176,093,258
Ensembl chr 2:176,091,804...176,093,254
|
|
G |
S1pr1 |
sphingosine-1-phosphate receptor 1 |
multiple interactions |
EXP |
Losartan inhibits the reaction [AGT protein modified form results in increased expression of S1PR1 mRNA]; Losartan inhibits the reaction [AGT protein modified form results in increased expression of S1PR1 protein] |
CTD |
PMID:29609002 |
|
NCBI chr 2:203,624,752...203,629,110
Ensembl chr 2:203,621,587...203,629,681
|
|
G |
Scarb1 |
scavenger receptor class B, member 1 |
multiple interactions |
ISO |
Losartan inhibits the reaction [[Dietary Fats co-treated with Cholesterol] results in decreased expression of SCARB1 mRNA] |
CTD |
PMID:18302760 |
|
NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647
|
|
G |
Sdc2 |
syndecan 2 |
decreases expression |
EXP |
Losartan results in decreased expression of SDC2 mRNA; Losartan results in decreased expression of SDC2 protein |
CTD |
PMID:15100363 |
|
NCBI chr 7:64,127,185...64,239,885
Ensembl chr 7:64,127,110...64,241,081
|
|
G |
Selp |
selectin P |
multiple interactions |
EXP |
Losartan inhibits the reaction [Estrogens deficiency results in increased expression of SELP protein] |
CTD |
PMID:19553526 |
|
NCBI chr13:76,476,229...76,511,846
Ensembl chr13:76,476,295...76,511,845
|
|
G |
Sfrp2 |
secreted frizzled-related protein 2 |
decreases response to substance |
EXP |
SFRP2 protein results in decreased susceptibility to Losartan |
CTD |
PMID:23875703 |
|
NCBI chr 2:169,089,517...169,097,064
Ensembl chr 2:169,089,517...169,097,063
|
|
G |
Slc22a12 |
solute carrier family 22 member 12 |
decreases activity affects response to substance decreases expression multiple interactions |
ISO |
Losartan results in decreased activity of SLC22A12 protein SLC22A12 protein affects the susceptibility to Losartan Losartan results in decreased expression of SLC22A12 mRNA [Losartan results in decreased activity of SLC22A12 protein] which results in decreased abundance of Uric Acid |
CTD |
PMID:18670416 PMID:20486468 |
|
NCBI chr 1:203,845,039...203,852,496
Ensembl chr 1:203,845,048...203,853,555
|
|
G |
Slc22a25 |
solute carrier family 22, member 25 |
multiple interactions |
ISO |
Losartan inhibits the reaction [SLC22A9 protein results in increased uptake of estrone sulfate] |
CTD |
PMID:17132213 |
|
NCBI chr 1:205,338,698...205,498,486
Ensembl chr 1:205,338,699...205,433,085
|
|
G |
Slc2a9 |
solute carrier family 2 member 9 |
multiple interactions |
ISO |
Losartan inhibits the reaction [SLC2A9 protein results in increased uptake of Uric Acid] |
CTD |
PMID:19587147 |
|
NCBI chr14:72,328,334...72,461,981
Ensembl chr14:72,328,320...72,461,981
|
|
G |
Slc9a3 |
solute carrier family 9 member A3 |
multiple interactions |
ISO |
Losartan inhibits the reaction [Ammonium Chloride results in increased expression of NHE3 protein] |
CTD |
PMID:18287403 |
|
NCBI chr 1:29,124,633...29,167,912
Ensembl chr 1:29,124,674...29,167,417
|
|
G |
Snai1 |
snail family transcriptional repressor 1 |
multiple interactions |
ISO |
ICG 001 promotes the reaction [Losartan inhibits the reaction [AGT protein results in increased expression of SNAI1 protein]]; Losartan inhibits the reaction [AGT protein results in increased expression of SNAI1 protein]; Losartan promotes the reaction [ICG 001 inhibits the reaction [AGT protein results in increased expression of SNAI1 protein]] |
CTD |
PMID:28578904 |
|
NCBI chr 3:156,248,479...156,252,969
Ensembl chr 3:156,248,485...156,252,969
|
|
G |
Sod2 |
superoxide dismutase 2 |
decreases activity |
EXP |
Losartan results in decreased activity of SOD2 protein |
CTD |
PMID:18765277 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sod3 |
superoxide dismutase 3 |
multiple interactions |
ISO |
Losartan inhibits the reaction [AGT protein results in increased expression of SOD3 protein] |
CTD |
PMID:10400907 |
|
NCBI chr14:58,610,104...58,615,845
Ensembl chr14:58,609,958...58,615,990
|
|
G |
Sparc |
secreted protein acidic and cysteine rich |
decreases expression |
EXP |
Losartan results in decreased expression of SPARC mRNA |
CTD |
PMID:15100363 |
|
NCBI chr10:39,516,394...39,538,252
Ensembl chr10:39,516,406...39,538,396
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
multiple interactions |
EXP |
Losartan inhibits the reaction [AGT protein results in increased cleavage of SREBF1 protein]; Losartan inhibits the reaction [AGT protein results in increased expression of SREBF1 mRNA]; Losartan inhibits the reaction [AGT protein results in increased phosphorylation of SREBF1 protein] |
CTD |
PMID:19109942 PMID:25398788 |
|
NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
decreases phosphorylation |
ISO |
Losartan results in decreased phosphorylation of STAT3 protein |
CTD |
PMID:33380422 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
decreases secretion multiple interactions decreases activity decreases expression increases expression |
ISO EXP |
Losartan results in decreased secretion of TGFB1 protein Losartan inhibits the reaction [Diethylnitrosamine results in increased expression of TGFB1 protein] [Losartan results in decreased activity of AGT protein] which results in decreased activity of TGFB1 protein Losartan results in decreased expression of TGFB1 mRNA; Losartan results in decreased expression of TGFB1 protein Losartan results in increased expression of TGFB1 protein [Losartan co-treated with Cilazapril] inhibits the reaction [Doxorubicin results in increased expression of TGFB1 protein]; [Losartan co-treated with Nifedipine] results in decreased expression of TGFB1 mRNA; Losartan inhibits the reaction [Carbon Tetrachloride results in increased expression of TGFB1 protein]; Losartan inhibits the reaction [Carbon Tetrachloride results in increased secretion of TGFB1 protein]; Losartan inhibits the reaction [Doxorubicin results in increased expression of TGFB1 protein]; Losartan inhibits the reaction [Paraquat results in increased expression of TGFB1 mRNA] |
CTD |
PMID:11369837 PMID:12930639 PMID:12937228 PMID:15331931 PMID:15573910 PMID:16191423 PMID:17330452 PMID:17666919 PMID:17784886 PMID:21152098 PMID:25233898 PMID:29859236 More...
|
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions decreases expression |
EXP |
Losartan inhibits the reaction [Paraquat results in increased expression of TIMP1 mRNA]; Losartan inhibits the reaction [Simvastatin results in decreased expression of TIMP1 mRNA]; Simvastatin inhibits the reaction [Losartan results in decreased expression of TIMP1 mRNA] |
CTD |
PMID:20137537 PMID:25233898 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Timp2 |
TIMP metallopeptidase inhibitor 2 |
decreases expression multiple interactions |
EXP |
Losartan results in decreased expression of TIMP2 mRNA Losartan inhibits the reaction [Simvastatin results in decreased expression of TIMP2 mRNA]; Simvastatin inhibits the reaction [Losartan results in decreased expression of TIMP2 mRNA] |
CTD |
PMID:20137537 |
|
NCBI chr10:103,541,199...103,590,611
Ensembl chr10:103,531,505...103,590,611
|
|
G |
Tjp1 |
tight junction protein 1 |
decreases expression |
EXP |
Losartan results in decreased expression of TJP1 protein |
CTD |
PMID:18400868 |
|
NCBI chr 1:118,849,838...119,094,492
Ensembl chr 1:118,849,838...119,094,432
|
|
G |
Tnc |
tenascin C |
decreases expression |
EXP |
Losartan results in decreased expression of TNC mRNA |
CTD |
PMID:15100363 |
|
NCBI chr 5:77,375,851...77,460,712
Ensembl chr 5:77,375,851...77,460,624
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions decreases expression |
ISO EXP |
Losartan affects the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Losartan inhibits the reaction [[Shiga Toxin 1 co-treated with TNF protein] results in increased activity of F3 protein]; Losartan inhibits the reaction [AGT protein modified form promotes the reaction [[Shiga Toxin 1 co-treated with TNF protein] results in increased activity of F3 protein]]; Losartan inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Losartan inhibits the reaction [TNF protein results in increased expression of VEGFA mRNA]; Losartan inhibits the reaction [TNF protein results in increased expression of VEGFA protein]; T 0070907 inhibits the reaction [Losartan inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]] Losartan inhibits the reaction [Diethylnitrosamine results in increased expression of TNF protein] Losartan results in decreased expression of TNF protein Losartan inhibits the reaction [bisphenol A results in increased expression of TNF mRNA]; Losartan inhibits the reaction [Carbon Tetrachloride results in increased secretion of TNF protein] |
CTD |
PMID:15573910 PMID:17299153 PMID:18060435 PMID:22124178 PMID:23875703 PMID:29859236 PMID:30677511 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tomm20 |
translocase of outer mitochondrial membrane 20 |
decreases expression |
EXP |
Losartan results in decreased expression of TOMM20 mRNA |
CTD |
PMID:18765277 |
|
NCBI chr19:54,925,197...54,935,188
Ensembl chr19:54,923,402...54,935,198
|
|
G |
Tp53 |
tumor protein p53 |
affects expression |
EXP |
Losartan affects the expression of TP53 protein |
CTD |
PMID:22000973 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tsc22d1 |
TSC22 domain family, member 1 |
multiple interactions |
EXP |
Losartan inhibits the reaction [AGT protein results in increased expression of TSC22D1 mRNA] |
CTD |
PMID:26464165 |
|
NCBI chr15:51,750,489...51,850,958
Ensembl chr15:51,749,510...51,850,958
|
|
G |
Twist1 |
twist family bHLH transcription factor 1 |
multiple interactions |
ISO |
Losartan inhibits the reaction [AGT protein results in increased expression of TWIST1 protein] |
CTD |
PMID:28578904 |
|
NCBI chr 6:50,674,910...50,676,904
Ensembl chr 6:50,674,678...50,677,653
|
|
G |
Ucp2 |
uncoupling protein 2 |
decreases expression multiple interactions |
ISO EXP |
Losartan results in decreased expression of UCP2 mRNA; Losartan results in decreased expression of UCP2 protein Losartan inhibits the reaction [AGT protein results in increased expression of UCP2 mRNA] |
CTD |
PMID:17508912 PMID:19109942 |
|
NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611
|
|
G |
Ucp3 |
uncoupling protein 3 |
multiple interactions |
EXP |
Losartan inhibits the reaction [AGT protein results in increased expression of UCP3 mRNA] |
CTD |
PMID:19109942 |
|
NCBI chr 1:154,815,777...154,828,764
Ensembl chr 1:154,815,777...154,828,762
|
|
G |
Vcam1 |
vascular cell adhesion molecule 1 |
multiple interactions |
EXP |
Losartan inhibits the reaction [Estrogens deficiency results in increased expression of VCAM1 protein] |
CTD |
PMID:19553526 |
|
NCBI chr 2:204,038,120...204,057,852
Ensembl chr 2:204,038,114...204,057,958
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions decreases expression |
ISO EXP |
Losartan inhibits the reaction [IL1A protein results in increased expression of VEGFA mRNA]; Losartan inhibits the reaction [IL1A protein results in increased expression of VEGFA protein]; Losartan inhibits the reaction [TNF protein results in increased expression of VEGFA mRNA]; Losartan inhibits the reaction [TNF protein results in increased expression of VEGFA protein]; Losartan promotes the reaction [AGT protein results in increased expression of VEGFA mRNA]; Losartan promotes the reaction [AGT protein results in increased secretion of VEGFA protein] Losartan inhibits the reaction [Diethylnitrosamine results in increased expression of VEGFA protein]; Losartan inhibits the reaction [Oxygen deficiency results in increased expression of VEGFA protein] Losartan inhibits the reaction [Cyclosporine results in increased expression of VEGFA protein] Losartan results in decreased expression of VEGFA mRNA; Losartan results in decreased expression of VEGFA protein |
CTD |
PMID:12110003 PMID:17299153 PMID:17481528 PMID:22188725 PMID:25511041 PMID:29859236 More...
|
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vegfc |
vascular endothelial growth factor C |
decreases expression |
ISO |
Losartan results in decreased expression of VEGFC mRNA |
CTD |
PMID:19771429 |
|
NCBI chr16:37,712,408...37,827,657
Ensembl chr16:37,712,262...37,827,848
|
|
G |
Vim |
vimentin |
multiple interactions |
ISO |
Losartan inhibits the reaction [AGT protein results in increased expression of VIM protein] Losartan inhibits the reaction [AGT protein results in increased expression of VIM protein]; Losartan inhibits the reaction [Silicon Dioxide results in increased expression of VIM protein] |
CTD |
PMID:28578904 PMID:33007385 |
|
NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187
|
|
G |
Wnt1 |
Wnt family member 1 |
multiple interactions |
ISO |
Losartan inhibits the reaction [AGT protein results in increased expression of WNT1 mRNA]; Losartan inhibits the reaction [AGT protein results in increased expression of WNT1 protein] |
CTD |
PMID:28578904 |
|
NCBI chr 7:129,938,604...129,942,651
Ensembl chr 7:129,938,604...129,942,651
|
|
G |
Wt1 |
WT1 transcription factor |
multiple interactions |
ISO |
Losartan inhibits the reaction [AGT protein results in decreased expression of WT1 protein] |
CTD |
PMID:28578904 |
|
NCBI chr 3:91,566,540...91,613,653
Ensembl chr 3:91,567,001...91,613,643
|
|
|
G |
Slc22a25 |
solute carrier family 22, member 25 |
multiple interactions |
ISO |
losartan carboxylic acid inhibits the reaction [SLC22A9 protein results in increased uptake of estrone sulfate] |
CTD |
PMID:17132213 |
|
NCBI chr 1:205,338,698...205,498,486
Ensembl chr 1:205,338,699...205,433,085
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
decreases expression |
ISO |
macitentan results in decreased expression of ABCB1 mRNA |
CTD |
PMID:28369585 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
decreases expression |
ISO |
macitentan results in decreased expression of ABCC2 mRNA |
CTD |
PMID:28369585 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
decreases expression |
ISO |
macitentan results in decreased expression of ABCC3 mRNA |
CTD |
PMID:28369585 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Slc10a1 |
solute carrier family 10 member 1 |
decreases expression |
ISO |
macitentan results in decreased expression of SLC10A1 mRNA |
CTD |
PMID:28369585 |
|
NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670
|
|
|
G |
Ace2 |
angiotensin I converting enzyme 2 |
multiple interactions |
EXP |
PD 123319 inhibits the reaction [diminazene aceturate results in increased expression of ACE2 protein] |
CTD |
PMID:28688122 |
|
NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977
|
|
G |
Agt |
angiotensinogen |
multiple interactions decreases response to substance decreases activity |
ISO EXP |
[olmesartan co-treated with PD 123319] inhibits the reaction [AGT protein modified form results in increased abundance of Fatty Acids, Nonesterified]; [olmesartan co-treated with PD 123319] inhibits the reaction [AGT protein modified form results in increased secretion of and results in increased abundance of Triglycerides]; PD 123319 inhibits the reaction [AGT protein results in increased expression of MDM2 mRNA]; PD 123319 inhibits the reaction [AGT protein results in increased expression of MDM2 protein] PD 123319 results in decreased susceptibility to AGT protein PD 123319 results in decreased activity of AGT protein modified form PD 123319 affects the reaction [AGT protein promotes the reaction [PTPN6 protein binds to MTUS1 protein]]; PD 123319 inhibits the reaction [AGT protein results in increased abundance of Nitric Oxide]; PD 123319 inhibits the reaction [AGT protein results in increased expression of ANGPT1 mRNA]; PD 123319 inhibits the reaction [AGT protein results in increased expression of ANGPT2 mRNA]; PD 123319 inhibits the reaction [AGT protein results in increased expression of EDN1 protein]; PD 123319 inhibits the reaction [AGT protein results in increased expression of KDR mRNA]; PD 123319 inhibits the reaction [AGT protein results in increased expression of MAP2 protein]; PD 123319 inhibits the reaction [AGT protein results in increased expression of SPP1 mRNA]; PD 123319 inhibits the reaction [AGT protein results in increased expression of SPP1 protein]; PD 123319 inhibits the reaction [AGT protein results in increased expression of TEK mRNA]; PD 123319 inhibits the reaction [AGT protein results in increased expression of TUBB3 protein]; PD 123319 inhibits the reaction [AGT protein results in increased expression of UBE2V2 protein]; PD 123319 inhibits the reaction [AGT protein results in increased expression of VEGFA mRNA]; PD 123319 inhibits the reaction [AGT protein results in increased expression of VEGFA protein]; PD 123319 promotes the reaction [AGT protein results in increased abundance of Prostaglandins E] PD 123319 inhibits the reaction [AGT protein results in increased expression of UBE2V2 mRNA]; PD 123319 inhibits the reaction [AGT protein results in increased expression of UBE2V2 protein]; PD 123319 inhibits the reaction [AGT protein results in increased phosphorylation of MAPK1 protein]; PD 123319 inhibits the reaction [AGT protein results in increased phosphorylation of MAPK3 protein]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of CYBB mRNA]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of CYBB protein]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX1 mRNA]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX1 protein]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX4 mRNA]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTRAP mRNA]]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTRAP protein]]]; PD 123319 inhibits the reaction [CGP 42112A promotes the reaction [[AGT protein co-treated with Rotenone] results in increased expression of AGTR2 protein]]; PD 123319 inhibits the reaction [CGP 42112A promotes the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTR2 mRNA]]] |
CTD |
PMID:9176287 PMID:9519251 PMID:11115077 PMID:14597853 PMID:14638905 PMID:14718351 PMID:15007106 PMID:16003179 PMID:16769992 PMID:17068200 PMID:18206046 PMID:18300857 PMID:19041135 PMID:19246637 PMID:25446015 More...
|
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Agtr2 |
angiotensin II receptor, type 2 |
multiple interactions decreases activity increases expression decreases expression |
ISO EXP |
[PD 123319 binds to and results in decreased activity of AGTR2 protein] inhibits the reaction [candesartan results in increased expression of NOS3 protein]; PD 123319 binds to and results in decreased activity of AGTR2 protein PD 123319 inhibits the reaction [CGP 42112A promotes the reaction [[AGT protein co-treated with Rotenone] results in increased expression of AGTR2 protein]]; PD 123319 inhibits the reaction [CGP 42112A promotes the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTR2 mRNA]]] PD 123319 results in decreased activity of AGTR2 protein PD 123319 results in increased expression of AGTR2 mRNA; PD 123319 results in increased expression of AGTR2 protein PD 123319 results in decreased expression of AGTR2 mRNA [PD 123319 binds to and results in decreased activity of AGTR2 protein] which affects the susceptibility to Phenylephrine; [PD 123319 results in decreased activity of AGTR2 protein] inhibits the reaction [Valsartan results in increased abundance of Cyclic GMP]; [PD 123319 results in decreased activity of AGTR2 protein] which results in decreased susceptibility to Estradiol; [PD 123319 results in decreased activity of AGTR2 protein] which results in decreased susceptibility to Valsartan; PD 123319 binds to and results in decreased activity of AGTR2 protein |
CTD |
PMID:9336375 PMID:9740612 PMID:11509473 PMID:11893553 PMID:15807884 PMID:16982965 PMID:18300857 PMID:18388195 PMID:18551021 PMID:19151255 PMID:25446015 More...
|
|
NCBI chr X:112,119,673...112,124,060
Ensembl chr X:112,120,228...112,124,057
|
|
G |
Agtrap |
angiotensin II receptor-associated protein |
multiple interactions |
ISO |
PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTRAP mRNA]]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [AGT protein promotes the reaction [Rotenone results in increased expression of AGTRAP protein]]] |
CTD |
PMID:25446015 |
|
NCBI chr 5:158,507,427...158,519,036
Ensembl chr 5:158,508,749...158,519,036
|
|
G |
Angpt1 |
angiopoietin 1 |
multiple interactions |
EXP |
PD 123319 inhibits the reaction [AGT protein results in increased expression of ANGPT1 mRNA] |
CTD |
PMID:14638905 |
|
NCBI chr 7:73,528,345...73,783,953
Ensembl chr 7:73,531,486...73,784,067
|
|
G |
Angpt2 |
angiopoietin 2 |
multiple interactions |
EXP |
PD 123319 inhibits the reaction [AGT protein results in increased expression of ANGPT2 mRNA] |
CTD |
PMID:14638905 |
|
NCBI chr16:71,088,364...71,138,805
Ensembl chr16:71,088,364...71,138,804
|
|
G |
Bdkrb2 |
bradykinin receptor B2 |
multiple interactions |
ISO |
PD 123319 affects the reaction [BDKRB2 affects the abundance of 6-Ketoprostaglandin F1 alpha] |
CTD |
PMID:16514058 |
|
NCBI chr 6:124,472,317...124,502,497
Ensembl chr 6:124,472,566...124,502,497
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
EXP |
PD 123319 inhibits the reaction [Streptozocin results in increased expression of CCL2 mRNA] |
CTD |
PMID:15284299 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
EXP |
PD 123319 inhibits the reaction [Ethylene Glycol results in increased expression of CCL5 protein] |
CTD |
PMID:16284884 |
|
NCBI chr10:68,322,826...68,327,365
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Cybb |
cytochrome b-245 beta chain |
multiple interactions |
ISO |
PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of CYBB mRNA]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of CYBB protein]] |
CTD |
PMID:25446015 |
|
NCBI chr X:13,360,583...13,392,517
Ensembl chr X:13,359,430...13,392,586
|
|
G |
Edn1 |
endothelin 1 |
multiple interactions |
EXP |
PD 123319 inhibits the reaction [AGT protein results in increased expression of EDN1 protein] |
CTD |
PMID:15007106 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Jak2 |
Janus kinase 2 |
multiple interactions |
ISO |
PD123319 co-treated with losartan inhibits the reaction [Angiotensin II increases phosphorylation of JAK2 protein in liver] |
RGD |
PMID:22613986 |
RGD:127285667 |
NCBI chr 1:226,995,334...227,054,381
Ensembl chr 1:226,995,334...227,054,189
|
|
G |
Kdr |
kinase insert domain receptor |
multiple interactions |
EXP |
PD 123319 inhibits the reaction [AGT protein results in increased expression of KDR mRNA] |
CTD |
PMID:14638905 |
|
NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018
|
|
G |
Kng2 |
kininogen 2 |
multiple interactions |
EXP ISO |
PD 123319 inhibits the reaction [benazepril promotes the reaction [Valsartan results in increased expression of KNG1 protein modified form]]; PD 123319 inhibits the reaction [Valsartan promotes the reaction [benazepril results in increased expression of KNG1 protein modified form]] PD 123319 affects the reaction [KNG1 affects the abundance of Nitric Oxide] |
CTD |
PMID:11509473 PMID:16514058 |
|
NCBI chr11:77,913,876...77,936,247
Ensembl chr11:77,909,612...78,002,971
|
|
G |
Map2 |
microtubule-associated protein 2 |
multiple interactions |
EXP |
PD 123319 inhibits the reaction [AGT protein results in increased expression of MAP2 protein] |
CTD |
PMID:17068200 |
|
NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
PD 123319 inhibits the reaction [AGT protein results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:19041135 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
PD 123319 inhibits the reaction [AGT protein results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:19041135 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
multiple interactions |
ISO |
PD 123319 inhibits the reaction [AGT protein results in increased expression of MDM2 mRNA]; PD 123319 inhibits the reaction [AGT protein results in increased expression of MDM2 protein] |
CTD |
PMID:18206046 |
|
NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
|
|
G |
Mtus1 |
microtubule associated scaffold protein 1 |
multiple interactions |
EXP |
PD 123319 affects the reaction [AGT protein promotes the reaction [PTPN6 protein binds to MTUS1 protein]] |
CTD |
PMID:17068200 |
|
NCBI chr16:51,202,497...51,347,791
Ensembl chr16:51,253,562...51,347,793
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
EXP |
PD 123319 inhibits the reaction [Ethylene Glycol results in increased expression of NFKB1 protein] |
CTD |
PMID:16284884 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nos3 |
nitric oxide synthase 3 |
multiple interactions |
ISO |
[PD 123319 binds to and results in decreased activity of AGTR2 protein] inhibits the reaction [candesartan results in increased expression of NOS3 protein] |
CTD |
PMID:18551021 |
|
NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166
|
|
G |
Nox1 |
NADPH oxidase 1 |
multiple interactions |
ISO |
PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX1 mRNA]]; PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX1 protein]] |
CTD |
PMID:25446015 |
|
NCBI chr X:97,279,058...97,332,291
Ensembl chr X:97,279,056...97,302,236
|
|
G |
Nox4 |
NADPH oxidase 4 |
multiple interactions |
ISO |
PD 123319 inhibits the reaction [CGP 42112A inhibits the reaction [[AGT protein co-treated with Rotenone] results in increased expression of NOX4 mRNA]] |
CTD |
PMID:25446015 |
|
NCBI chr 1:140,900,886...141,078,844
Ensembl chr 1:140,901,097...141,077,406
|
|
G |
Prkce |
protein kinase C, epsilon |
increases expression |
EXP |
PD 123319 results in increased expression of PRKCE protein |
CTD |
PMID:11893553 |
|
NCBI chr 6:7,965,048...8,451,966
Ensembl chr 6:7,965,048...8,451,719
|
|
G |
Ptpn6 |
protein tyrosine phosphatase, non-receptor type 6 |
multiple interactions |
EXP |
PD 123319 affects the reaction [AGT protein promotes the reaction [PTPN6 protein binds to MTUS1 protein]] |
CTD |
PMID:17068200 |
|
NCBI chr 4:157,526,034...157,550,783
Ensembl chr 4:157,526,035...157,550,984
|
|
G |
Spp1 |
secreted phosphoprotein 1 |
multiple interactions |
EXP |
PD 123319 inhibits the reaction [AGT protein results in increased expression of SPP1 mRNA]; PD 123319 inhibits the reaction [AGT protein results in increased expression of SPP1 protein] |
CTD |
PMID:11115077 |
|
NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162
|
|
G |
Tek |
TEK receptor tyrosine kinase |
multiple interactions |
EXP |
PD 123319 inhibits the reaction [AGT protein results in increased expression of TEK mRNA] |
CTD |
PMID:14638905 |
|
NCBI chr 5:109,607,077...109,733,805
Ensembl chr 5:109,607,077...109,733,804
|
|
G |
Tubb3 |
tubulin, beta 3 class III |
multiple interactions |
EXP |
PD 123319 inhibits the reaction [AGT protein results in increased expression of TUBB3 protein] |
CTD |
PMID:17068200 |
|
NCBI chr19:51,457,187...51,466,243
Ensembl chr19:51,457,184...51,466,243
|
|
G |
Ube2v2 |
ubiquitin conjugating enzyme E2 V2 |
multiple interactions |
ISO EXP |
PD 123319 inhibits the reaction [AGT protein results in increased expression of UBE2V2 mRNA]; PD 123319 inhibits the reaction [AGT protein results in increased expression of UBE2V2 protein] |
CTD |
PMID:16769992 PMID:17068200 |
|
NCBI chr11:85,304,528...85,338,430
Ensembl chr11:85,304,526...85,336,369
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
EXP |
PD 123319 inhibits the reaction [AGT protein results in increased expression of VEGFA mRNA]; PD 123319 inhibits the reaction [AGT protein results in increased expression of VEGFA protein]; PD 123319 inhibits the reaction [Streptozocin results in increased expression of VEGFA mRNA]; PD 123319 inhibits the reaction [Streptozocin results in increased expression of VEGFA protein] |
CTD |
PMID:14638905 PMID:14718351 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|